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Abstract 
Sex hormonal variations cause bodily changes reflecting their systemic functions. This 
project was designed to define the influence of sex hormones on systemic function in men 
with prostate cancer (PC) receiving contemporary androgen deprivation therapy (ADT) with 
luteinising hormone-releasing hormone agonists (LHRHa). LHRHa induced suppression of 
sex hormones results in multiple serious toxicities of which the cognitive, skeletal and 
psychosocial aspects were addressed in this project.  
Acute castration appears to cause cognitive problems in some men with PC. In order 
to identify the neuropathology of such cognitive decline, positron emission tomography (PET) 
was used along with a battery of validated neuropsychological tests, documenting for the first 
time an increased global and regional cortical neuroinflammatory response in patients with PC 
experiencing cognitive deterioration since being on LHRHa.  
Bone mineral density, a commonly employed measure of bone mass, lacks accuracy 
in predicting bone strength and fracture risk. The present work showed bone volume fraction 
(a newer non-invasive metric of bone mass derived using computed tomography imaging) to 
be highly correlated with bone strength measured ex-vivo, thereby demonstrating its potential 
for use in clinical assessments. Levels of serum bone-specific alkaline phosphatase, a marker 
of skeletal metabolism, were also measured to assess bone changes in the early stages of 
LHRHa therapy but no change was observed. 
Metabolic derivatives of sex hormones have been suggested to influence psycho-
socio-sexual behaviour via odour signalling. The current work, investigating effects of 
castration on odour, showed no change in the olfactory perception of odour samples provided 
by men on LHRHa treatment. 
These pilot data and observations will help shape future work that may not only 
improve quality of life outcomes in men with PC undergoing ADT but also benefit patients 
suffering from other clinical conditions involving physiological, pathological or therapeutic 
changes in sex hormone levels. 
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1. Background 
1.1 Reproduction 
Reproduction is a fundamental property of living organisms ensuring continuity of their 
species, which from a biological viewpoint constitutes the foremost purpose of life. The two 
basic strategies employed by animals for reproduction include asexual and sexual 
reproduction.  
Table 1 Comparison of sexual and asexual reproduction [1, 2] 
Sexual Reproduction Asexual reproduction 
Combination of gametes in a process 
called fertilization 
No gametes involved 
Genetic information contributed by two 
parents 
Genetic information contributed by a 
single parent 
More resources are required e.g. time, 
energy, availability of partner 
Lesser resources required 
Genetic variation results from sexual 
reproduction only 
No genetic variation via asexual 
reproduction 
Genetic variation helps a species 
survive. During adverse environmental 
changes or increased competition for 
resources, organisms with varying 
genetic traits may exhibit a survival 
advantage 
Fluctuating environment changes or 
increased competition may prove fatal 
for all organisms due to lack of genetic 
variation 
 
Due to genetic recombination, offspring 
may lose the genes favourable to a 
particular stable environment 
Offspring acquires same parental traits 
that are well adapted to a particular 
environment 
Complex organisms tend to reproduce 
sexually e.g. humans 
Simple organisms tend to reproduce 
asexually e.g. bacteria 
 
In asexual reproduction, an individual produces genetically identical offspring by 
mitosis, thus allowing it to clone itself. Sexual reproduction involves the union of sex cells 
known as gametes. Gametes, having half the number of chromosomes of the original cell 
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(haploid), are produced by meiosis. Sperm (male gamete) and egg (female gamete) fuse 
together during fertilization to form a diploid cell, zygote, which is the first cell of the progeny. 
Table 1 gives a comparison between sexual and asexual reproduction. Sexual reproduction 
remains the most common method of reproduction in vertebrates including humans [1, 2].  
 
 
Figure 1 Scanning electron micrograph of human X and Y chromosomes  
(Left: Y chromosome, Right: X chromosome) 
Adapted from http://www.anatomybox.com/tag/sem/ 
 
Sexual reproduction evolved with the development of sex chromosomes. Humans 
have 46 chromosomes of which 44, called autosomes, are members of identical pairs. The 
remaining two i.e. X and Y chromosomes, however, do not form an identical pair and are 
referred to as the ‘sex chromosomes’ (Figure 1). In humans, females have two X 
chromosomes whereas males have one X and one Y chromosome. This difference in sex 
chromosomes gives rise to the anatomical and physiological dissimilarities in the two genders 
which are the pre-requisites for human sexual reproduction. Biochemical parameters also vary 
between males and females in addition to the structural and functional distinctions. Amongst 
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these biochemical factors are reproductive hormones which perform an important role in 
sexual development and reproduction.  
 
1.2 Sex hormones 
A hormone is a chemical messenger produced in one cell or gland that affects the 
function of its target cell or organ in another part of the body. The term hormone is derived 
from the Greek word ‘horme’ meaning ‘impulse’. The major reproductive hormones, also 
termed sex hormones, control the growth and function of the reproductive organs and the 
development of secondary sex characteristics. Oestrogens and progestogens are typically 
referred to as female sex hormones while androgens are termed male sex hormones. 
However, these hormones are present in both sexes but at different concentrations, also 
varying with age and phases of menstrual cycle in females (Table 2). The word oestrogen 
takes its origins from the Greek words ‘oistros’ meaning ‘mad desire’ and ‘genein’ meaning ‘to 
produce’. Similiarly, androgen is derived from the Greek ‘andros’ meaning ‘male’. 
  
24 
 
Table 2 Reference ranges for serum sex hormone levels in adults [3] 
Sex hormone Subject Range 
Androgens 
Testosterone 
 
Male 
10-35 nmol/L 
300-1000 ng/dL 
Female 
0.7-3 nmol/L 
20-85 ng/dL 
Dihydrotestosterone 
 
Male 30-85 ng/dL 
Androstenedione 
 
Male & Female 60-270 ng/dL 
Oestrogens 
Oestradiol 
 
Male 
50-200 pmol/L 
14-55 pg/mL 
Female 
(Pre-menopausal) 
70-600pmol/L 
19-160 pg/mL 
Female 
(Post-menopausal) 
< 130 pmol/L 
< 35 pg/mL 
Progestogens Progesterone 
Male 
0.27-0.9 ng/mL 
0.86-2.9 nmol/L 
Female 
(Mid-Luteal phase of 
Menstrual cycle) 
17-92 nmol/L 
6-29ng/mL 
Female (Post-
menopausal) 
< 1 ng/mL 
< 3 nmol/L 
 
1.2.1 Biosynthesis 
The biosynthesis of steroid hormones involves multiple enzyme systems expressed in 
different tissues. Steroid hormones are synthesized from cholesterol which is a 27-C lipid 
molecule containing cyclopentanophenantherene steroid nucleus (Figure 2) [4].  
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Figure 2 Molecular structure of cholesterol 
Adapted from http://www.satorihealth.co.uk/articles.php?id=15 
Cholesterol is composed of three regions; a hydrocarbon tail, a steroid ring structure 
nucleus with 4 hydrocarbon rings, and a hydroxyl group. 
 
Enzymatic alterations in the cholesterol molecule produce three classes of steroid 
hormones: 1) mineralocorticoids e.g. aldosterone 2) glucocorticoids e.g. cortisol and 3) 
gonadocorticoids e.g. androgens, oestrogens and progesterone. These gonadocorticoids are 
classed together because of their actions on reproductive physiology and commonly referred 
to as sex hormones or sex steroids [5]. Testosterone, dihydrotestosterone (DHT) and 
androstenedione are the major body androgens while oestrogens include oestradiol, oestrone 
and oestriol. Dehydroepiandrosterone (DHEA), derived from cholesterol, is the precursor 
molecule for the synthesis of androgens and oestrogens. 
The conversion of cholesterol to pregnenolone, which occurs in the mitochondria, is 
the first and rate limiting step in the steroidogenic pathway catalysed by the enzyme 
cholesterol mono-oxygenase [6]. Microsomal cytochrome P450 isoform 17 (CYP17; having 
17α-hydroxylase and 17,20-lyase activities) enzymes present in the endoplasmic reticulum 
act on pregnenolone to yield carbon (C)-19 steroid derivative dehydroepiandrosterone. 
Subsequently, a series of reductive and isomerisation steps lead to the production of 
androstenedione and testosterone (Figure 3).  
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Figure 3 Biosynthetic pathway of sex hormones 
Adapted from https://pharmaceuticalintelligence.files.wordpress.com/2015/02/steroid-hormone-synthesis.jpg 
 
Testosterone is converted into DHT by the action of 5α-reductase. Androstenedione 
and testosterone serve as substrates for oestrogen biosynthesis and are converted into 
oestrone and oestradiol respectively by aromatisation (Figure 3). Pregnenolone also yields 
progesterone by the enzymatic action of 3β-hydroxysteroid dehydrogenase which is further 
converted into aldosterone, cortisol or androstenedione (Figure 3) [6-9]. 
 
1.2.2 Sites of synthesis 
The activity of enzyme systems and the physiological nature of the steroidogenic cells 
determine the type of steroid hormones produced and secreted by them.  In males, about 95% 
of testosterone production takes place in the Leydig cells of testes and the remaining 5% in 
adrenal glands. Around 85% of androstenedione in blood stream comes from testes and 
adrenals while the rest of it is produced in other tissues (adipose, skin, liver) from DHEA [8]. 
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Ovaries are the principal sites for oestrogen biosynthesis in females, accounting for 
approximately 95% of systemic oestradiol. Extragonadal sites include adipose tissue, bone 
and brain which serve as the main sources of oestrogen following menopause while during 
pregnancy, placenta also contributes to the oestrogen pool [7, 10-12]. 
  
1.2.3 Quantitative and qualitative control 
The quantitative control of steroid biosynthesis is provided by two proteins identified 
with cholesterol transport across the mitochondrial membrane which are the steroidogenic 
acute regulatory protein (StAR) and translocator protein (TSPO), formerly called 
peripheral benzodiazepine receptor (PBR). Both these proteins reside on the outer 
mitochondrial membrane and facilitate movement of cholesterol into the mitochondria [13].  
Furthermore, the direction of pregnenolone towards sex hormone synthesis in the 
adrenal glands is dependent on the microsomal enzymes which provides the qualitative 
regulation. C-19 precursors of sex steroids are only produced when 17α-hydroxylase and 
17,20 lyase activities of CYP17 are present (Figure 3). Absence of one or both of these 
activities leads to synthesis of glucocorticoids or mineralocorticoids [8].  
 
1.2.4 Regulation and metabolism of sex hormones 
The levels of sex hormones in the body are regulated primarily by hypothalamic-
pituitary-gonadal (HPG) axis signalling which is involved in the production of most sex steroids. 
Local tissue level modulation of sex hormone metabolism is another important regulatory 
mechanism. 
 
1.2.4.1 Hypothalamic-pituitary-gonadal axis 
The principal regulation of sex steroid synthesis is carried out by a negative feedback 
effect on HPG axis exerted through downstream production of sex hormones (Figure 4) [6]. 
Luteinising hormone releasing hormone (LHRH), also known as gonadotropin releasing 
28 
 
hormone (GnRH), is a hypothalamic peptide transported via hypothalamic-hypophyseal portal 
venous system to the anterior pituitary gland. LHRH acts on the anterior pituitary which in turn 
secretes the glycopeptides luteinising hormone (LH) and follicle-stimulating hormone (FSH) 
into the circulation. In males, FSH regulates spermatogenesis in the testes by binding to its 
surface receptors on the Sertoli cells while LH acts on testicular Leydig cells to initiate 
androgen synthesis. In females, LH acts on ovarian theca cells to stimulate oestrogen 
synthesis while FSH affects granulosa cells to initiate follicular growth and maturation during 
menstrual cycle. Mid-cycle LH surge from the anterior pituitary triggers ovulation and LH also 
leads to the generation of corpus luteum from the residual follicle [14] [15].  
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Figure 4 Feedback regulation of gonadal hormone production via HPG axis 
Adapted from http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/endocrinology/male-hypogonadism/ 
Negative feedback inhibition of GnRH (LHRH) and LH release results from binding of 
testosterone to androgen receptors present in the hypothalamic neurons and anterior 
pituitary 
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1.2.4.2 Tissue level regulation 
Sex hormones undergo tissue level metabolism which is important for inactivation and 
excretion of excess hormones. The inactivation involves metabolism of testosterone into 
oestradiol and dihydrotestosterone. Oestradiol is metabolised to yield oestrone and 
dihydrotestosterone is converted into androsterone and 3α-diol, which possess little sex 
steroid activities. Irreversible conjugation of oestrone, androsterone and 3α-diol with uridine 
diphospho- (UDP) glucuronic acid inactivates these metabolites by impeding their binding to 
steroid receptors. Glucuronidation also converts these metabolites into a water-soluble form 
for excretion in the urine and/or faeces [16].  
 
1.2.4.3 Transport 
Sex hormones in the circulation are transported bound to plasma proteins including 
sex hormone binding globulin (SHBG) and albumin. The specific transporter SHBG is 
synthesised in the liver and has a higher affinity for testosterone than oestradiol. SHBG binds 
two-thirds of the circulating testosterone and one-third of oestradiol while only 2% of 
testosterone and oestradiol is free. The remaining testosterone and oestradiol are bound to 
albumin but they are considered bioavailable due to low binding affinity [9]. 
 
1.2.5 Sex hormone receptors 
Sex hormones exert their biologic actions mainly by interacting with their receptors. 
Sex hormone receptors belong to a subgroup of nuclear receptors (Figure 5) called steroid 
hormone receptors (SHR) which include the androgen receptor (AR), the oestrogen receptors 
alpha and beta (ERα and ERβ), and the progesterone receptor (PR) [16, 17].  
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Figure 5 Structural organisation of a typical nuclear receptor 
Adapted from [17] 
Nuclear receptor comprises a variable NH2-terminal region (A/B), a conserved 
deoxyribonucleic acid (DNA)-binding domain (C), a variable linker region (D), and a 
conserved E/F region that contains the ligand-binding domain 
 
1.2.5.1 Mechanism of action of sex hormones 
The classical genomic mechanism of sex hormone action involves binding of the sex 
hormone to its receptor. SHRs in the absence of ligand are sequestered in large complexes 
with heat shock proteins (HSP). The binding of hormone brings about a distinct conformational 
change in receptor structure, eliciting dissociation of HSPs. The hormone-receptor dimer then 
binds to the target genome at highly specific hormone response elements (HREs), initiating 
gene transcription and production of specific messenger ribonucleic acids (mRNA). 
Translation of these mRNAs in the cytoplasm leads to synthesis of proteins which bring about 
physiological changes in the target tissue that are characteristic of the sex hormone (Figure 
6) [17, 18]. Sex steroids have also been shown to alter cellular activity by exerting acute non-
genomic effects through their interaction with plasma membrane-bound non-nuclear receptors 
such as G protein-coupled receptors and ion channels [18, 19].  
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Figure 6 Mechanism of action of sex hormones 
Adapted from http://biologysemester58.wikispaces.com/Homeostasis 
1) Sex hormone diffuses into target cell 2) binds to its receptor 3) Nuclear 
translocation of hormone-receptor dimer 4) the dimer attaches to DNA at response 
element 5) transcriptional activation of specific gene 6) protein synthesis 
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1.3 Sex hormones in foetal development 
The embryo remains in a sexually indifferent stage till about the sixth week of 
embryonic development whereby it has the potential to develop into either male or female 
phenotype. Sex chromosomes direct gonadal differentiation in the seventh week after 
conception. The embryo at that stage has Müllerian and Wolffian ducts and rudimentary 
external genitalia. Embryonic development into male phenotype is triggered by expression of 
the Y-chromosomal SRY gene (sex-determining region of Y chromosome) which controls the 
formation of testes (Figure 7) [20]. Anti-Müllerian hormone secreted by Sertoli cells of the 
testes causes degeneration of Müllerian ducts, while the production of high amounts of 
testosterone from foetal Leydig cells in males directs differentiation of Wolffian ducts into 
epididymis, vas deferens, seminal vesicles and prostate (Figure 7). In the females, absence 
of SRY gene and subsequent lack of testosterone and anti-Müllerian hormone production 
leads to regression of Wolffian ducts while Müllerian ducts differentiate into fallopian tubes, 
uterus and vagina with simultaneous development of female external genitalia [21]. 
  
34 
 
 
Figure 7 Role of SRY gene in the development of male phenotype 
Adapted from http://en.wikipedia.org/wiki/Sexual_differentiation_in_humans 
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1.4 Sex hormones in pubertal development 
Puberty is the period of attaining sexual maturity that encompasses changes including 
growth of the reproductive organs and development of secondary sexual characteristics [22]. 
These physical changes at puberty occur as a result of elevated secretion of gonadal sex 
hormones by activation of the HPG axis (Figure 8). The HPG axis at pre-pubertal stage is 
highly sensitive to negative feedback inhibition from very small concentrations of sex 
hormones. Closer to puberty, the sensitivity of HPG axis to negative feedback from sex 
hormones is decreased. This leads to a gradual rise in the levels of gonadotrophic hormones 
and subsequent growth of the gonads, which in turn causes accelerated production of sex 
hormones. There is a 45-fold increase in testosterone in adult boys as compared to childhood 
levels while oestradiol levels are up to 9 times higher in adult girls as compared to pre-pubertal 
levels [23]. In adolescent males, testicular growth is driven primarily by testosterone while 
other androgens cause growth of pubic hair and long bones and the development of 
characteristic masculine voice and body odour. In adolescent females, oestradiol causes 
growth of breasts, promotes fusion of long bones following growth spurts and female-type fat 
distribution, and initiates ovulation and menstruation (Figure 8) [23, 24]. 
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Figure 8 Pubertal changes as a result of increased sex hormone production 
Adapted from http://cnx.org/contents/14fb4ad7-39a1-4eee-ab6e-3ef2482e3e22@6.27:190/Anatomy_&_Physiology 
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More than half a century ago, Tanner described five stages of puberty based on visible 
secondary sexual characteristics which is still considered the gold standard for assessing 
pubertal development [24]. Table 4 describes key features of Tanner staging. 
Table 3 Tanner staging of pubertal development [24] 
 
Tanner 
Stage 
 
Genitalia (Males) 
 
Breast (Females) 
Pubic Hair  
(Both males and 
females) 
I Childhood size Pre-adolsecent None 
II Enlargement of scrotum / 
testes 
Breast bud Sparse, straight, long 
III Penis grows in length, 
further enlargement of 
testes 
Areolar diameter 
enlarges 
Darker, curling, 
increased amount 
IV Penis grows in length 
and diameter, scrotum 
darkens, testes enlarge 
Secondary mound, 
separation of contours 
Coarse, curly, adult type 
V Adult shape and size Mature female Adult, extend to thighs 
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1.5 Role of sex hormones in adult physiology 
Androgens and oestrogens are present in both sexes but at different concentrations 
and there are temporal changes in concentrations as well e.g. during menstrual cycle, 
menopause. Further, sex hormone receptors are distributed in reproductive (including testes, 
prostate, uterus, ovaries) as well as many non-reproductive organs e.g. brain, bone, heart etc. 
The biological role of sex hormones in adults is therefore, not limited to reproduction and they 
affect all tissues where their receptors are distributed. 
 
1.5.1 Cardiovascular system 
The expression of ERs and AR in hearts and blood vessels suggests a role of sex 
hormones in cardiovascular system (CVS) physiology [25, 26]. Studies have demonstrated an 
atheroprotective role of oestrogen, facilitated by its beneficial effects on lipid profile (reduced 
low-density lipoprotein and elevated high-density lipoprotein) as well by its mediation of 
vasodilation through increased production of nitric oxide and decreased production of 
endothelin-1 from arterial endothelium and decreased intracellular calcium in arterial smooth 
muscle [26, 27]. 
Premenopausal women have a relatively lower incidence of CVS disease than age-
matched men but the rates become similar with the loss of oestrogen in postmenopausal 
women [28]. Previously, observational studies showed a decline in CVS events in 
postmenopausal women receiving hormone replacement therapy (HRT) with oral oestrogen 
but later trials demonstrated an increase in the risk of thromboembolism and CVS events with 
oral oestrogen given as HRT [25, 26, 29]. 
The role of androgens in CVS physiology is complex and far less studied than 
oestrogen. Androgens have been associated with atherosclerotic CVS disease in men through 
their adverse effects on lipids metabolism and hypertension. Conversely, the gradual decline 
in androgen levels in elderly males as a result of the ageing process has also been linked to 
hypertension, diabetes and atherosclerosis [28]. Studies in athletes using anabolic steroids 
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have suggested detrimental effects of testosterone on heart function, showing it to be 
associated with cardiac hypertrophy, impaired cardiac function and an increased risk of 
myocardial infarction [25]. However, studies of long-term testosterone replacement in 
hypogonadal elderly men have demonstrated reduced risk of CVS morbidity and mortality [30]. 
 
1.5.2 Body composition 
Sex steroids are involved in regulating muscle metabolism and function as well as body 
composition. Women have a higher body fat percentage and subcutaneous adipose tissue as 
compared to men [31]. In men, androgens are known to play a critical role in maintaining 
muscle mass, strength and body composition which is mediated by activation of ARs found in 
myocytes and adipocytes. The direct anabolic effects of androgens leading to skeletal muscle 
hypertrophy have been shown in numerous studies. [32]. In the first 3 years after menopause, 
there is a decrease in lean body mass (LBM) of about 4% which as a consequence leads to 
decline in muscle strength in postmenopausal women. Androgen therapy in such women has 
been shown to increase muscle mass and decrease fat mass [33]. Hypogonadism in elderly 
men is associated with sarcopaenia and increased adiposity which result in physical frailty, 
reduced mobility and increased risk of falls [34]. Testosterone levels in elderly males have 
been shown to have a positive correlation with muscle mass and a negative correlation with 
fat mass [32]. 
Results from an experimental study of healthy adult male volunteers undergoing 
androgen suppression followed by androgen replacement with or without aromatase inhibitors 
showed that loss of muscle mass and strength occurs because of androgen deficiency while 
body fat gain results mainly from the lack of oestrogen (owing to suppression of aromatisation) 
[35]. Cross-sectional analysis from another recent study showed testosterone (free and total) 
to be inversely correlated to anthropometric parameters including body weight, body mass 
index (BMI: weight in kilograms / height in metres squared), fat mass and waist-to-hip ratio. 
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Free oestradiol was positively correlated with fat mass and oestradiol:testosterone ratio was 
positively correlated with all measured variables of body composition [36]. 
  
1.5.3 Cognition 
Sexual differentiation of the brain occurs during intrauterine and neonatal period. 
Masculinisation of brain anatomy and physiology during these early stages of development is 
brought about by secretion of testosterone and its actions either directly through AR activation 
or via aromatisation to oestradiol and subsequent ER activation [19, 37]. Sex based structural 
dimorphism is seen in many parts of the brain including hypothalamus, limbic system, higher 
cognitive centres and structures of the midbrain, brainstem and basal forebrain. Both ERs and 
ARs are located in these brain regions but their regional expression is not uniform [37, 38]. 
Gender differences in cognitive functioning have been demonstrated with men exhibiting a 
superior visuospatial ability and women displaying superior ability in verbal fluency and 
perceptual speed tasks [39].  
Oestradiol, in addition to its ovarian synthesis, is also synthesized in the brains of adult 
males and females where it serves to regulate several functions related to cognition, pain 
perception and behaviour. A neuroprotective function of oestradiol has been suggested in 
neurodegenerative disorders (e.g. Alzheimer’s disease; AD) and traumatic brain injury [38, 40, 
41]. Specific cognitive domains such as verbal memory and fluency are influenced by 
oestrogen as reflected in the performance variations on these tasks seen across the menstrual 
cycle as well as the decline observed at menopause. Some studies have shown that 
symptomatic postmenopausal women receiving HRT with oestrogen show improvements in 
verbal memory and reasoning. Association of HRT with a decreased risk of dementia has also 
been shown [42, 43]. 
The age-related decline in testosterone levels is associated with a decline in cognitive 
functions in men and the cognitive domains most commonly affected include memory and 
visuospatial function [44]. A neuroprotective role of testosterone has been suggested in 
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laboratory and animal studies. Compared to healthy controls, lower levels of testosterone are 
seen in patients suffering from AD, a neuropathological condition characterised by impairment 
of cognitive ability [45]. However, testosterone supplementation in hypogonadal men does not 
seem to offer cognitive benefits, possibly because of the inability of standard 
neuropsychological assessments in picking up the subtle improvements [45, 46]. 
 
1.5.4 Bone health 
Androgens and oestrogens are involved in normal bone physiology and skeletal 
homeostasis. Rapid bone growth and development of skeletal differences in adult males and 
females during adolescence are regulated by sex hormones [47]. Both ARs and ERs are 
expressed in all bone cells including osteoblasts, osteoclasts, osteocytes and bone marrow 
stromal cells, reflecting a role of both androgens and oestrogens in preserving bone health 
[48]. 
Oestrogen preserves bone integrity through its anti-resorptive function mediated 
predominantly by activation of ERα. It inhibits osteoclast formation and increases osteoclast 
apoptosis via modulation of signaling pathways including FAS/FAS ligand, and receptor 
activator of nuclear factor kappa B (RANK)/RANK ligand [49]. The bone-sparing properties of 
oestrogen have been studied widely in the setting of female menopause. Accelerated bone 
loss and subsequent development of osteoporosis occur as a result of oestrogen deficiency 
seen in postmenopausal women. HRT with oestrogen has been shown to prevent this bone 
loss and improve bone mineral density (BMD) [47, 50]. 
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Figure 9 Physiological effects of sex hormones on bone cells 
Adapted from Skeletal Care Academy; Cancer Treatment induced bone loss DMO-IHQ-AMG-187-2012- August-NP 
Androgens promote bone formation and restrain bone resorption directly or indirectly through 
conversion to oestrogens  
 
Androgens stimulate the differentiation and proliferation of osteoblasts causing 
increase in mineralisation and also lead to a surge in the synthesis of extracellular matrix 
proteins (type 1 collagen, osteocalcin, osteonectin). Testosterone has been suggested to have 
a dual mode of action for its proskeletal effects involving both AR and ER through its 
conversion into oestradiol via aromatisation (Figure 9) [33, 51]. A recent study of testosterone 
replacement in postoperative hypogonadal males with pituitary tumours showed significantly 
improved lumbar spine BMD compared to baseline BMD (4.5% improvement, p-value 0.028) 
over a mean observation period of 56 months [52]. Osteoporosis and bone fractures are 
common among the elderly due to age-related androgen deficiency. Androgen replacement 
has been shown to improve BMD in these men [34]. 
 
1.5.5 Sexual function 
Human sexual function is complex and involves integration of several neural, vascular 
and muscular processes. Sex hormones coordinate these processes and contribute to sexual 
43 
 
function in both males and females. These effects are mediated by ARs and ERs present in 
areas of central nervous system regulating sexual behaviour as well as in the reproductive 
organs [53]. Testosterone and DHT maintain spermatogenesis during adult life by activation 
of ARs in Leydig and Sertoli cells [4].Testosterone has an important role in maintaining sexual 
interest and arousal in men. Testosterone replacement in hypogonadal men has been shown 
to improve duration of erection, nocturnal erections, penile rigidity and sexual satisfaction [54, 
55].  
Oestrogens are known to maintain normal female sexual and reproductive physiology. 
Both oestradiol and testosterone peak at ovulation and studies have shown sexual interest in 
females to rise in the follicular phase and reach maximum at ovulation [56, 57]. Oestrogen 
deficiency following menopause negatively alters libido, sexual arousal and satisfaction but 
the degree of these changes varies considerably. Menopausal reduction in oestrogen is also 
associated with genital shrinkage and HRT with oestrogen has been shown to improve these 
aspects of female sexual dysfunction [58]. In men, oestradiol is also produced in the testis 
from testosterone via testicular aromatase activity. Moreover, ERs are present in male genital 
apparatus suggesting their role in normal male sexual function [53]. Studies in aromatase 
deficient men have suggested exogenous oestrogen replacement to improve sexual interest 
[59]. 
  
1.5.6 Metabolic effects 
Sex differences in metabolic profiles of men and women suggest specific roles of sex 
hormones in energy metabolism. In young adult males, lipid deposition is predominantly 
visceral as compared to females where lipids are deposited subcutaneously as well in the 
lower body [31]. Androgen deficiency in men is linked with the development of insulin 
resistance, impaired glucose tolerance, central adiposity and adverse lipid profile (elevated 
total cholesterol and triglycerides and low high density liporotein (HDL)-cholesterol. On the 
other hand, low testosterone levels are commonly observed in men with type 2 diabetes 
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mellitus and metabolic syndrome [60, 61]. Testosterone replacement therapy in hypogonadal 
men has previously been shown to improve glucose metabolism and reduce fat content [62]. 
However, a recent randomized, placebo-controlled trial of testosterone therapy in obese 
diabetic men has shown no beneficial effect on insulin sensitivity or visceral adiposity [63].  
  
1.5.7 Odour signalling 
 Pheromones are airborne chemo-signals secreted by an individual and having specific 
hormonal, neural and behavioural influences on conspecifics (individual belonging to the same 
species). Pheromones are known to affect animal behaviour and recent evidence suggests 
that humans can detect pheromones through olfaction and show specific responses [64].  
Humans possess uniquely discernible body odours which are affected by pheromones, 
gender, age and several other factors. Exposure to body odour of other individuals has been 
shown to elicit psychological and physiological responses. Body odour provides cues about a 
potential sexual partner’s health, reproductive status and genetic quality. It is considered a 
signal of physical attractiveness and sexual appeal and is associated with masculinity and 
dominance [65]. Men have been shown to perceive female scents as pleasant and sexually 
attractive during the high fertility phase of the menstrual cycle as compared to the low fertility 
phase [66]. Women show a greater preference for body odours of males with low fluctuating 
asymmetry during the high fertility phase of their menstrual cycles [67] and these enhanced 
sexual preferences are associated with testosterone levels in males [68]. Monozygotic twins 
have matching body odours suggesting important genetic influences [69, 70]. Major 
histocompatibility complex (MHC) genes have been shown to affect body odour [71]. Age 
differences in odours of men have been documented [72] but it is not known whether that is 
due to changes in their gonadal hormone profile, which in fact, is known to diminish with 
advancing age [34].  
Axillary odour, readily identifiable due to its pungent nature, is generally referred to as 
body odour [73]. Axillary secretions are known to contain various odoriferous volatile 
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chemicals which may act as pheromones [74]. Androstadienone, a steroidal metabolite 
yielded from the sex hormone biosynthetic pathway, is one such compound that has been 
implicated as a human pheromone. It is synthesised from androstadienol, a derivative of 
pregnenolone [64]. Pregnenolone also serves as the precursor molecule of human sex 
hormones [6]. Androstadienone is found in bodily secretions including sweat, semen and 
saliva and its concentration is particularly high in axillary sweat of men [64]. Studies have 
reported favourable effects of androstadienone, particularly in females, on sexual behaviour, 
attraction, mood and mate selection. Exposure to androstadienone has also been shown to 
enhance concentration and pain perception, increase cortisol levels and activate brain regions 
involved in social cognition [75-80].   
Animal studies suggest a potentially direct role of sex hormones as pheromones. 
Behavioural and physiological changes have been observed in female mice through 
cutaneous or nasal absorption of oestradiol excreted in male urine [81].  
 
1.6 Sex hormones and their clinical implications 
Owing to the wide array of biological functions carried out by sex hormones, the 
aetiopathology, symptomatology and therapeutic management of many clinical conditions are 
linked to sex hormone homeostasis. These include menopause, andropause, contraception, 
gender dysphoria, polycystic ovarian syndrome (PCOS) and hormone-sensitive cancers. 
Surgical and/or pharmacologically induced alterations in sex hormone levels in these 
conditions offer an opportunity to study the complex biological roles of sex hormones. 
Variations in sex hormone levels, whether physiological, pathological or pharmacological, lead 
to bodily changes which are reflective of their systemic functions.  
 
1.6.1 Menopause 
The physiological cessation of menstruation in women (at a mean age of 51 years) 
occurring as a result of exhaustion of ovarian follicles and consequent decline in the levels of 
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oestrogen and progesterone is termed the menopause [82]. Secondary effects due to 
menopausal sex hormone changes include vasomotor symptoms (hot flashes), depression, 
sleep disturbance, vaginal atrophy, osteoporosis and cognitive dysfunction [83-88]. HRT with 
oestrogen alone or in combination with progesterone is used to relieve menopause-related 
symptoms and dosage, timing of administration, duration all affect the outcomes [50, 82, 89].  
 
1.6.2 Andropause 
 Andropause, also termed late-onset hypogonadism, is the male counterpart of female 
menopause. Androgen levels in men begin to diminish in the mid-thirties at an annual rate of 
1-1.5%. Nearly a third of men between 70-79 years have testosterone levels lower than 
normal, and more than two-thirds have reduced levels of bioavailable testosterone [90]. This 
reduction in androgens as a result of ageing manifests as andropause which is characterised 
by symptoms including reduced libido, erectile dysfunction, loss of musculature, increased 
adiposity, osteopaenia, lack of energy, psychological disturbance and cognitive impairment 
[91, 92]. Testosterone replacement therapy is used for treating andropausal symptoms but 
definitive evidence about its benefits and risks is lacking currently [93]. 
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1.6.3 Contraception 
Hormonal contraception is widely used by women of reproductive age. In the United 
States of America (USA), half of the women use some form of hormonal contraception 
including short-term (oral contraceptive pills, transdermal patches) or long term methods 
(depot injections, subcutaneous implants and intrauterine contraceptive devices) [94]. Oral 
contraceptive pills are the most common form of hormonal contraception used by a quarter of 
women of reproductive age in the United Kingdom (UK) while 1 in 10 women use long-acting 
hormonal contraceptive techniques [95].  
Hormonal contraceptives, containing combined oestrogen/progestogen or 
progesterone only preparations, work primarily by reducing endogenous ovarian production of 
oestrogen and progestogen via negative feedback inhibition. The resultant drop in circulating 
levels of oestrogen and progesterone leads to suppression of ovulation [96, 97]. Some 
experimental studies have shown the feasibility of using testosterone preparations (given in 
oral, gel and injectable forms) as a means of hormonal contraception in men [98]. 
 
1.6.4 Polycystic ovarian syndrome 
 Polycystic ovarian syndrome (PCOS) is an extremely common endocrinopathy 
affecting 5% to 15% of the women of reproductive age the world over [99]. The aetiology of 
this heterogeneous disorder is complex with genetic influences, life-style factors and 
gestational environment all implicated in its development [100]. PCOS is classified by the 
presence of two of the three diagnostic traits namely 1) biochemical or clinical features of 
hyperandrogenaemia 2) Chronic ovulatory dysfunction and 3) polycystic ovaries, after ruling 
out other causes that may have similar features [100, 101].  
Hyperandrogenaemia in PCOS usually results in hirsutism, acne and male pattern 
alopecia. Oligo-anovulatory cycles often manifest as oligomenorrhea, amenorrhea, 
dysfunctional uterine bleeding and problems with fertility [102, 103]. PCOS is also associated 
with psychological disturbances, increased risk of endometrial carcinoma, obstructive sleep 
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apnoea and features of metabolic syndrome including obesity, insulin resistance, impaired 
glucose tolerance and dyslipidaemia [104]. Management of PCOS is mainly directed at 
alleviating the symptoms and includes pharmacological interventions and lifestyle 
modifications to correct hormonal imbalances and metabolic disturbances [100, 101]. 
 
1.6.5 Gender dysphoria 
 Gender dysphoria, also referred to as transgenderism or gender identity disorder, is a 
condition in which the individual identifies with the gender opposite to his/her own biological 
sex. Such individuals exhibit cross-gender behaviours, express constant uneasiness with their 
assigned gender roles and desire to alter their physical appearance to conform to their self-
perceived gender [105]. Unlike disorders of sexual development, gender dysphoria is not 
associated with any structural or functional abnormality [106]. Management of affected 
persons is aimed at making their bodies congruent to their internal sense of gender and 
enhancing their psychological well-being [107]. Treatment requires a multidisciplinary 
approach requiring psychological, hormonal, cosmetic and surgical interventions [108, 109].  
Hormone therapy is an important component of the treatment and involves alteration 
of the sex hormonal milieu of the subject to bring about the desired physical and psychological 
change [110]. Hormone therapy for male-to-female transgenderism requires administration of 
oestrogens and androgen-suppressing agents such as luteinising hormone releasing hormone 
agonists (LHRHa) or anti-androgens. LHRHa suppress testicular testosterone production by 
inhibiting the HPG axis whereas anti-androgens block the effects of circulating androgens by 
binding to ARs. Female-to-male transformation requires testosterone administration [111]. 
Depending on the type of sex hormone administered and its formulation, dosage and route of 
administration, hormone therapy in transgender subjects can result in adverse metabolic 
and/or thromboembolic side effects [112].  
49 
 
1.6.6 Hormone-sensitive cancers 
 Sex hormones regulate the normal development and function of many organs, 
particularly the reproductive organs, and are also implicated in the development and 
progression of cancers in these organs [113, 114]. Prostate and testicular cancers in men and 
breast, endometrial and ovarian cancers in women are the typical hormone-sensitive cancers. 
These cancers are very common and are a major cause of cancer-related mortality worldwide 
[115]. It has been suggested that cellular proliferation driven by sex hormones increases the 
likelihood of genetic mutations which can get accumulated over time and lead to the 
development of a malignant phenotype [116].  Endocrine therapies targeting endogenous sex 
hormones are employed for treatment of hormone-dependent cancers [6] e.g. oestrogen 
levels are lowered to treat breast cancer by agents causing ovarian ablation such as LHRHa, 
aromatase inhibitors or selective oestrogen receptor modifier (SERM).  Anti-oestrogens, which 
competitively bind ERs, are also used in the management of hormone- sensitive breast cancer 
[117]. 
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1.7 Prostate cancer 
 
1.7.1 Prostate gland 
 The term ‘prostate’ has its roots in the Greek word ‘prohistani’, meaning ‘to stand in 
front of’. Herophilus used this term in 335 B.C. to describe the organ located ‘in front of the 
urinary bladder’ [118]. The prostate is situated just inferior to the bladder in the pelvic cavity 
(Figure 10). It is a fibromuscular and glandular organ, normally weighing about 20 grams and 
roughly conical in shape. It has a base, an apex, an anterior, a posterior and two lateral 
surfaces. Prostatic secretions contribute to volume of semen and serve as nourishment for 
sperms. Prostate gland has four zones; anterior, transitional, central and peripheral (Figure 
11).  
 
 
Figure 10 Anatomical relations of prostate gland 
http://www.macmillan.org.uk/Cancerinformation/Cancertypes/Prostate/Aboutprostatecancer/Theprostate.aspx 
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The unrestricted irregular proliferation of abnormal cells of prostate gland origin is 
called prostate cancer (PC). Prostate gland is a common site of cancer development in males 
and nearly two-thirds of all PCs are found within the peripheral zone [119]. Almost all PCs are 
adenocarcinomas and other rare types of cancers in the prostate gland include 
neuroendocrine tumours, small cell cancers, transitional cells cancers and sarcomas [120]. 
The characteristic pathological features of PC include genetic aberrations, resistance to 
apoptosis, chronic inflammation, angiogenesis and metastasis [121]. 
 
 
Figure 11 Zonal anatomy of prostate gland 
Adapted from http://wholelifeprostate.com/prostate.html 
 
1.7.2 Prostate cancer incidence 
Prostate cancer (PC) is a major international health problem at present. It is one of the 
commonest life threatening malignancies afflicting men the world over [122]. In the year 2012, 
more than a million men were globally estimated to have been diagnosed with PC, with 
variable incidence rates across different geographical regions [123]. PC accounts for about 
10% of all male cancers worldwide, with this figure being ~5% in less developed countries 
and  ~15% in developed countries [124].  
PC is the commonest malignancy and second most common cause of cancer death 
affecting men in the western world [125]. In the USA alone, the incidence rate for PC is nearly 
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a quarter of a million diagnoses each year and almost 30,000 deaths. PC is the second most 
common cancer after skin cancer and second most common cause of cancer mortality after 
lung cancer in the USA. About 1 in every 7 American men is likely to be diagnosed with PC 
and 1 in 38 will die from it [120]. Almost half a million men are diagnosed with PC in Europe 
each year and a tenth of a million die from it. In the UK, PC is the commonest male cancer, 
accounting for 24% of all new male cancer diagnoses. Around 42,000 British men were 
diagnosed with PC in the year 2011-2012 and more than 10,000 died from it [123]. 
 
1.7.3 Risk factors 
 PC is a multifactorial disease and exact aetiology is not clear yet. It has been 
suggested that genetic causes as well as environmental and life style factors contribute to the 
development of PC. In addition to these genetic and life style factors, variation in PC incidence 
and mortality rates across the different parts of the world can be attributed to healthcare 
differences in cancer screening and registration [124]. 
 
1.7.3.1 Age 
 PC is a considered a disease of the elderly as ageing is associated with an increased 
risk [120, 126]. PC is very rare in men below the age of 40 years, but more than two-thirds of 
all PC diagnoses are in men older than 65 years. Autopsy studies have revealed a 50% 
prevalence of PC in men between 70-80 years of age [124].  
 
1.7.3.2 Family history 
 Increased incidence of PC has been observed in families suggesting hereditary 
tendency [126]. It has been reported that 10-15% of patients with PC have at least one family 
member who is also affected. First-degree relatives of patients have a two to three-fold 
increased relative risk for developing PC [127]. The clustering of PC in families can be due to 
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shared gene pool, exposure to common environmental factors and/or diet or perhaps due to 
chance alone considering the high prevalence of PC. 
 
1.7.3.3 Racial predisposition 
 Race is an important risk factor for PC. The risk of developing PC and its associated 
mortality is highest among African-Americans, Caucasians have an intermediate risk while 
Asian men carry the lowest risk. This racial predisposition has been attributed to common 
genetics and exposure to similar environmental and/or life-style influences [120, 126].  
 
1.7.3.4 Genetic susceptibility 
Genetic factors have been estimated to account for half of the risk of PC. Genome-
wide association studies (GWAS), which scan the genome for genetic polymorphisms 
occurring frequently in a particular disease than in the normal population, have identified 
almost one hundred such variants which have a multiplicative effect on increasing the risk of 
PC development. These genetic variations are suggested to be a major reason of familial 
aggregation of PC. Genetic mutations of the tumour suppressor genes breast cancer antigen 
1 (BRCA1) and breast cancer antigen 2 (BRCA2) have also been linked with a 10% and 25% 
increased risk of PC respectively [127, 128]. 
 
1.7.3.5 Diet and nutrition 
 The role of dietary factors in development of PC has been studied since long but results 
are conflicting and no clear evidence has become available as yet [129]. Excessive 
consumption of red meat, fats, dairy products and alcohol have been associated with an 
increased risk of PC.  Fresh fruits and vegetables are thought to decrease the risk [120, 124, 
129]. Obesity is linked to PC development and regular exercise is associated with a reduced 
risk. A strong correlation between BMI at the time of PC diagnosis and PC-specific mortality 
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has been shown recently and this is more marked in overweight or obese patients with 
aggressive disease [130].  
 
1.7.3.6 Other influences 
Results from a recent study have shown male pattern baldness to be associated with 
an increased risk of aggressive PC [131]. It has been indicated that childhood height is 
associated with increased risk of PC and PC-specific mortality [132]. Sexually transmitted 
diseases and vasectomy have also been implicated as risk factors for PC [120]. Medications 
including aspirin, statins and anti-diabetics were previously suggested to reduce the risk of PC 
but a recent study did not find any such protective effect [133].   
 
1.7.4 Clinical presentation 
PC has no specific clinical features. An enlargement of the prostate can lead to 
development of the symptoms of urinary outflow obstruction such as frequency, nocturia, 
urgency, hesitancy and weak urinary stream. These symptoms are commonly seen in patients 
with benign prostatic hyperplasia (BPH). Haematuria, erectile dysfunction and perineal pain 
are some other symptoms associated with PC and patients with metastatic disease may also 
present with bone pain [120]. 
 
1.7.5 Diagnostic tools 
PC diagnosis is based on a detailed clinical history followed by a digital rectal 
examination (DRE), a laboratory test for measuring serum levels of prostate-specific antigen 
(PSA) and imaging. A definitive diagnosis is established on histopathologic evidence of cancer 
following transrectal ultrasonography (TRUS)-guided prostate biopsy. 
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1.7.5.1 Digital rectal examination 
A DRE is done to assess the shape, size, symmetry, nodularity and degree of firmness 
of the prostate gland. PC may be detected by DRE if the tumour is located in the peripheral 
zone of the prostate gland and its volume is > 0.2 ml. A suspicious DRE indicates a need for 
biopsy [119, 134]. 
 
1.7.5.2 Prostate-specific antigen 
PSA is a glycoprotein and functions as a serine protease. PSA is secreted by the 
secretory epithelial cells of prostate gland and is a major seminal protein where it helps to 
liquefy semen and facilitate fertilisation (Figure 13) [135]. Disruption of the normal glandular 
architecture in malignancy allows PSA increased access to peripheral circulation. It has been 
suggested that PSA also plays a role in PC disease progression by enhancing tumour 
proliferation, invasion and metastasis [136]. PSA is currently the best available and most 
commonly used serum marker to identify men with a higher probability of having PC. An 
elevated PSA level > 2-3ng/ml, particularly at a younger age, is considered high enough to 
warrant further investigation [134]. Non-cancerous conditions such as BPH, prostatitis, 
ejaculation and recent urologic procedures including DRE and biopsy can also result in an 
elevated serum PSA [120]. 
 
 
Figure 12 PSA cleaves proteins involved in coagulation of semen [136] 
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1.7.5.3 Imaging 
Advancements in imaging technology have led to their increasing use in evaluating 
prostate cancer. TRUS, being inexpensive and easily available, is employed most frequently 
for PC detection. Magnetic resonance imaging (MRI) is useful in detection of PC particularly 
by enabling biopsy targeted at suspected regions. Other imaging techniques including 
computed tomography (CT), positron emission tomography (PET) and radionuclide bone 
scanning have no role in PC detection. The use of CT and PET imaging is limited to 
assessment of nodal involvement and/or distant metastases while bone scanning is solely 
employed for assessing the skeletal spread of cancer  [119, 137, 138].  
 
1.7.5.4 Biopsy 
The decision to perform prostate biopsy is made on the basis of clinical history, DRE 
and PSA result. Histological assessment of suspected specimens obtained usually with TRUS 
biopsy is considered the benchmark for diagnosing PC. Multiple needle biopsies (up to 12 
cores) are performed to seek histologic proof of cancer  Possible complications following 
biopsy procedures include haematuria, haematospermia, rectal bleeding, prostatitis, 
epididymitis and fever [134]. 
 
1.7.5.5 Staging 
Staging is a measure of the size and spread of tumour. Staging of PC is usually done 
by DRE, serum PSA measurement and radionuclide bone scan. CT, PET or MR imaging may 
also be employed for staging in certain clinical situations e.g. assessment of pelvic lymph 
nodes. Tumour-Node-Metastasis (TNM) system of staging is clinically useful for stratifying 
newly diagnosed PC into localised, advanced or metastatic disease (Table 4) [120, 134]. 
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Primary tumour (T) 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 Clinically inapparent tumour, not palpable or visible by imaging 
T1a Tumour incidental histologic finding in ≤5% of tissue resected 
T1b Tumour incidental histologic finding in >5% of tissue resected 
T1c Tumour identified by biopsy (because of elevated PSA level) 
T2 
Tumour confined within prostate; tumours found in 1 or both lobes on biopsy but not 
palpable or visible by imaging 
T2a Tumour involves one-half of 1 lobe or less 
T2b Tumour involves more than one-half of 1 lobe but not both lobes 
T2c Tumour involves both lobes 
T3 
Tumour extends through the prostatic capsule; invasion into the prostatic apex, or the 
prostatic capsule is classified not as T3 but as T2 
T3a Extracapsular extension (unilateral or bilateral) 
T3b Tumour invading seminal vesicle(s) 
T4 Tumour invades adjacent structures other than seminal vesicles 
Regional lymph nodes (N) 
NX Regional lymph nodes not assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in regional lymph node(s) 
Distant metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Non-regional lymph nodes(s) 
M1b Bone(s) 
M1c Other site(s) with or without bone disease 
Table 4 TNM staging for prostate cancer 
 
1.7.5.6 Grading 
Grading refers to the histological appearance of cancer cells. Gleason scoring system 
is employed for grading PC and is useful in predicting the clinical behaviour in terms of disease 
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progression and treatment outcomes. The two predominant tumour histologies are each given 
a score from 1-5, depending on the degree of differentiation. The two scores are added to 
assign a Gleason grade (low, moderate, high) to the tumour (Figure 13). Thus a high grade 
represents a poorly differentiated cancer that it is more likely to grow and spread aggressively 
[120].  
 
 
Figure 13 Gleason grading for prostate cancer 
Adapted from http://www.prostatehealth.org.au/home/about-prostate-cancer/staging-grading/ 
 
1.7.6 Treatment options for prostate cancer 
Several options are available for treating PC, offered and administered depending 
upon the stage and grade of the disease, patient preference and availability as well as the 
anticipated clinical outcomes. The current treatment strategies for PC include expectant 
management (watchful waiting or active surveillance), radical prostatectomy, radiation 
therapy, cryotherapy, androgen deprivation therapy (ADT) and chemotherapy. 
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1.7.6.1 Watchful Waiting 
Watchful waiting is a conservative approach of observing the patient until symptomatic 
progression after which palliative treatment is started to relieve symptoms due to tumour 
enlargement (urinary outflow obstruction) or metastasis (bone pain, vertebral fractures and 
spinal cord compression). Watchful waiting is considered for treating patients with localised 
disease having a limited life expectancy due to co-morbidity or for elderly patients with less 
aggressive cancers [120, 134, 139].  
 
1.7.6.2 Active surveillance 
Active surveillance involves frequent follow-ups and close monitoring of patients with 
DRE, PSA testing, TRUS and repeat biopsy. Active surveillance is reserved for localised low-
risk PC and helps treat only those patients who are more likely to get maximum benefit from 
radical treatment [140, 141]. Initiation of curative treatment (surgery or radiation therapy) is 
recommended in case of early indication of progression based on clinical examination and/or 
biochemical, ultrasonographic or histologic evidence [120, 134, 142]. 
 
1.7.6.3 Radical prostatectomy 
Radical prostatectomy (RP), an established curative option for low to intermediate risk 
localised disease [143], is a surgical intervention which involves complete excision of the 
prostate gland along with seminal vesicles. Almost half of the men diagnosed with localised 
PC undergo radical prostatectomy [140]. Retropubic or perineal RP are the traditional surgical 
approaches while newer minimally invasive techniques include laparoscopic or robot-assisted 
laparoscopic RP [144]. Complications of RP include excessive bleeding, infection, 
rectal/ureteral injuries, incontinence and impotence. Nerve-sparing RP aims to preserve the 
neurovascular bundle supplying the corpus cavernosum, thereby minimising the risk of 
developing erectile dysfunction following surgery [144, 145].  
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1.7.6.4 Radiation therapy 
Radiation therapy (RT), aimed at causing DNA damage to malignant cells, is a 
standard curative treatment for high risk localised PC administered commonly as either 
external beam radiation therapy (EBRT) or brachytherapy [143, 146]. About a quarter of all 
patients diagnosed with localised disease receive RT [140]. In EBRT, targeted radiation from 
an external source is given to the tumour over several weeks. Brachytherapy involves 
ultrasound-guided intra-prostatic placement of radiation pellets containing radioactive isotopes 
(Palladium-103 or Iodine-125). The possible complications of RT include obstructive urinary 
symptoms, rectal bleeding, diarrhoea and impotence [147]. 
 
1.7.6.5 Cryotherapy 
Cryotherapy is a minimally invasive modality employed in the treatment of primary 
localised and recurrent PC [148]. Though not used routinely due to lack of long-term 
comparative data with other local treatments, recent advancements have improved clinical 
outcomes from cryotherapy for localised disease [149]. Cryotherapy involves TRUS-guided 
transperineal insertion of hollow probes into the prostate to deliver gases (argon-helium 
mixture) at extremely low temperatures (up to -180oC) [148]. This leads to tissue ablation as 
a consequence of direct cellular injury and microcirculatory failure resulting from exposure to 
such extreme below freezing temperatures [150].  
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1.7.6.6 Androgen deprivation therapy 
PC was historically considered an autonomous untreatable disease and a diagnosis of 
PC was thought to be synonymous with imminent death. Not much was known about the 
biology of PC until 1941, when ground-breaking findings from the experiments of Charles 
Huggins (Figure 14) and co-workers revealed the androgen-dependent nature of PC. It was 
demonstrated that reduction in serum androgen levels of patients with metastatic PC by 
castration with surgical orchidectomy or administration of oral oestrogen ‘diethylstilboestrol’ 
(DES) induced retardation of tumour growth and improvement of symptoms. In the year 1966, 
Huggins was awarded the Nobel Prize in Physiology and Medicine for his revolutionary work 
which signalled the commencement of an era of development of therapies aimed at depleting 
androgens for the treatment of advanced disease  [113, 151, 152].  
 
Figure 14 Charles B Huggins (left) and Andrew V Schally (right) [152, 153] 
 
It is now known that PC cells, normal or malignant, require androgens for their growth 
and proliferation via activation of ARs. Testosterone, the major circulating androgen, is 
converted into DHT by the action of the enzyme 5α-reductase within the prostate cells. 
Intracellular DHT is almost 10 times more potent than testosterone and promotes androgen 
62 
 
signalling responsible for tumour progression. Withdrawal of androgens by ADT leads to PC 
regression [154, 155]. To-date, ADT remains the mainstay for treating advanced PC and it has 
undergone substantial evolution over the last five decades [156]. Table 5 lists the different 
modalities used as ADT for PC with their mechanisms of action. 
 
Table 5 ADT modalities and their mechanisms of action 
 
ADT Modality 
 
Mechanism of Action 
Surgical orchidectomy Removal of testes which are the principal source of 
testosterone, contributing > 90% to the circulating 
testosterone pool 
Diethylstilboestrol (DES; 
oral oestrogen) 
Negative feedback inhibition of the HPG-axis 
LHRH agonists 
(leuprolide, goserlin, 
triptorelin) 
Downregulation of pituitary LHRH receptors, decrease 
LH release which subsequently suppresses testosterone 
production 
LHRH antagonists 
(Degarelix) 
Inhibition of pituitary LHRH receptors directly 
Non-steroidal anti-
androgens (bicalutamide, 
flutamide, nilutamide) 
Competitive inhibition of AR activation by direct 
binding to AR ligand-binding sites 
Steroidal anti-androgens 
(cyproterone acetate) 
Blockade of enzyme CYP17 in adrenal steroid 
biosynthetic pathway, reduction in adrenal androgen 
production  
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1.7.6.6.1 Surgical orchidectomy 
Surgical orchidectomy (bilateral removal of testes) was one of the first used ADT 
modalities [151], resulting in a rapid decline in serum testosterone to castrate levels (< 50 
ng/dL or 1.7 nmol/L) as the testes are the principal source of circulating androgens (producing 
nearly 95% of total)  [8, 157]. Despite being a cost-effective means of ADT for PC, surgical 
orchidectomy is rarely performed these days particularly in the western world owing to the 
psychological trauma associated with it [158, 159].  
 
1.7.6.6.2 Oral oestrogen 
Around half a century ago, a synthetic oral oestrogen DES was used for treating 
metastatic PC, thus making it the first pharmacological agent for ADT. Oestrogens, sharing 
the same steroid nucleus as testosterone, suppress testicular production of androgens via a 
negative feedback loop inhibiting the HPG axis [6].  
DES was studied extensively by the ‘Veterans Administration Cooperative Urological 
Research Group’ (VACURG) who conducted a series of randomised clinical trials comparing 
DES to surgical orchidectomy for the treatment of newly diagnosed PC (8). Despite showing 
equivalent efficacy to surgical orchidectomy, DES was withdrawn from routine clinical use as 
the 5mg dose was shown to cause CVS toxicity in a third of treated patients with 15% 
experiencing a serious thromboembolic event [160]. However, subsequent trials showed 
cardiovascular mortality to be lower with low dose DES (1mg) as compared to high dose DES 
(5mg) without any change in the beneficial oncological effects [161].  
 
1.7.6.6.3 Luteinising hormone releasing hormone agonists 
The molecular structure of hypothalamic hormone LHRH, also called GnRH, was 
characterised by Andrew Schally’s (Figure 14) laboratory in 1971. Following the remarkable 
discovery, Schally and co-workers developed synthetic decapeptides that acted as agonists 
of LHRH. Unlike the pulsatile hypothalamic release, short half-life and moderate receptor 
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binding affinity of LHRH, chronic administration of synthetic LHRHa or gonadotropin releasing 
hormone analogues (GnRHa) results in a continuous and prolonged action causing 
downregulation of pituitary receptors. The net effect is suppression of FSH and LH secretion 
from the anterior pituitary causing cessation of androgen production in the testicular Leydig 
cells and subsequent reduction of circulating testosterone [162]. Castrate levels of 
testosterone are achieved within a month of starting LHRHa therapy [157, 163]. Andrew 
Schally was awarded the Nobel Prize in Physiology and Medicine in 1977 for his pioneering 
work which led to LHRHa becoming a standard ADT modality [153]. 
LHRHa were shown to have a similar survival outcome to surgical orchidectomy or 
DES [164]. Due to their better psychological tolerability than surgical orchidectomy and 
improved CVS safety profile than high dose DES, LHRHa gained worldwide acceptance in the 
1980s and have since remained the treatment of choice for androgen sensitive advanced PC 
[156]. The commonly employed LHRHa agents include goserelin, leuprolide and triptorelin, 
given usually as subcutaneous depot injections on a monthly or three monthly basis [165].  
LHRHa are typically offered for long term therapy following a diagnosis of advanced 
(incurable) disease either at presentation and following failure of radical therapy with curative 
intent [165]. LHRHa are now also given for short term as adjuvant or neo-adjuvant to RT for 
localised disease after they were shown to improve clinical and survival outcomes [166]. 
LHRHa not only suppress serum concentration of testosterone to <5% of normal (castrate 
levels) but also result in an acute decline in oestrogen levels to <20% of normal (aromatisation 
of testosterone yields oestrogen in males) [6, 167]. As a consequence of diminished sex 
hormones, long term ADT with LHRHa has been associated with serious complications such 
as sarcopaenia, anaemia, sexual dysfunction and osteoporosis [168]. Intermittent ADT with 
LHRHa has been considered to overcome such toxicity. This involves cycling ADT with off-
treatment periods, allowing testosterone to recover above castrate levels during the treatment 
cessation phase. Survival outcomes similar to continuous ADT have been shown with 
intermittent ADT in metastatic PC [169] and potential benefits relating to body composition 
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changes have been suggested [170]. However current evidence appears inadequate in 
establishing intermittent ADT for routine clinical use [171, 172]. 
Initial exposure to LHRHa leads to a ‘testosterone flare reaction’, due to preliminary 
transient activation of HPG-axis which leads to a surge in the production of testosterone. In a 
few patients, this can cause complications such as exacerbation of bone pain from skeletal 
metastasis and worsening of urinary obstructive symptoms. The flare phenomenon is blocked 
by administering anti-androgens a week before starting LHRHa and continuing for 2-3 weeks 
afterward [163].  
 
1.7.6.6.4 Anti-androgens 
Anti-androgens, also called androgen antagonists, are oral agents that inhibit AR 
signalling by competitively blocking the AR ligand-binding sites. There are two distinct classes 
of anti-androgens; steroidal (cyproterone acetate) and non-steroidal (bicalutamide, flutamide 
and nilutamide). In addition to AR blockade, steroidal anti-androgens also exhibit 
progestogen-like activity that results in central HPG inhibition and decrease in serum 
testosterone [173].  
Anti-androgens are commonly employed for preventing the flare reaction from LHRHa 
therapy [163] and they have also been used in combination with LHRHa (combined androgen 
blockade; CAB). CAB was the first method of ADT shown to improve survival in patients with 
advanced disease as compared to surgical orchidectomy or DES [174].  
Suppression of testosterone synthesis in the testes does not completely eliminate 
serum androgens as adrenal production accounts for 5% of the circulating androgen pool [8]. 
Further, the potent androgen DHT is also synthesized locally in the prostate from sex hormone 
precursor DHEA produced in the adrenal glands. The residual androgens from a non-testicular 
origin stimulate PC growth and CAB has been used to enhance the efficacy of ADT by 
countering this effect [8, 175].  
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1.7.6.6.5 Luteinising hormone releasing hormone antagonists 
LHRH antagonist Degarelix is a newer ADT agent that binds to pituitary receptors and 
blocks the release of LH and FSH, without causing the flare reaction seen with LHRHa.  
Degarelix, currently available as a monthly depot injection, has been shown to induce a rapid 
decline in serum testosterone levels (96% patients achieve castrate levels within 3 days) and 
maintain castrate levels effectively [176]. Recent findings from analysis of pooled data of 
prospective randomised controlled trials (RCT) comparing degarelix to LHRHa suggest 
improvements in survival and musculoskeletal toxicity outcomes with degarelix [177]. 
 
1.7.6.7 Castration-resistant prostate cancer and its treatment 
Following initial response to ADT, PC invariably progresses to a state of resistance 
called castration-resistant prostate cancer (CRPC) which is associated with a poor prognosis 
and reduced survival. Continued AR signalling due to intratumoral androgen synthesis, AR 
mutations and AR overexpression has been suggested to propel disease progression despite 
castrate levels of testosterone achieved with conventional ADT [156, 178].  A number of novel 
treatments offering survival benefit for CRPC have recently been introduced [179, 180]. These 
include cytotoxic chemotherapy (docetaxel, cabazitaxel) [181], new ADT agents (abiraterone, 
enzalutamide) [182-184] and immunotherapy (sipuleucel-T) [185].  Low-dose oral DES (1-3 
mg) has also been demonstrated to be effective and safe as a CRPC treatment with a 5-10% 
rate of thromboembolic events [186, 187]. Table 6 lists the treatment options for CRPC and 
their mechanisms of action. The management of CRPC has been transformed with the 
introduction of these new agents but questions regarding their optimum timing, combination 
therapy and toxicity profile still need to be answered. 
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Table 6 Novel treatment options for castration-resistant prostate cancer 
 
Treatment 
 
Type 
 
Mechanism of Action 
Docetaxel, 
Cabazitaxel 
Cytotoxic 
chemotherapy 
Arrest tumour growth by binding to tubulin protein and 
causing cell cycle arrest 
Abiraterone  Androgen 
deprivation 
therapy 
Suppresses intratumoral androgen synthesis by inhibiting 
both 17-α-hydroxylase and 17,20 lyase activities of 
microsomal enzyme cytochrome P450 isoform-17 
Enzalutamide Anti-androgen Multi-step inhibition of androgen signalling cascade 
(competitive binding to AR, reduced nuclear 
translocation, impaired DNA binding)  
Sipuleucel-T Immunotherapy  Activated autologous cytotoxic T-cell vaccine targets 
prostatic acid phosphatase expressed by tumour cells 
DES Synthetic oral 
oestrogen 
Inhibits gonadal, extragonadal and intratumoral 
androgen synthesis 
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1.7.6.8 Toxicities of contemporary androgen deprivation therapy 
Contemporary ADT, usually achieved with LHRHa, is associated with multiple 
debilitating adverse effects including compromised bone health (osteoporosis and fragility 
fractures), vasomotor disturbances (hot flushes, night sweats), metabolic imbalances 
(dyslipidaemia, impairments in glucose homeostasis), sexual dysfunction (diminished libido, 
impotence), neuropsychological issues (depression, cognitive decline), changes in body 
composition (loss of musculature, central adiposity, weight gain), changes in sleep pattern, 
anaemia and various other systemic problems (increased susceptibility to CVS events, renal 
damage, decreased physical strength) [168, 188-193]. The constellation of ADT induced 
serious toxicities is labelled as ‘castration syndrome’ or ‘androgen deprivation syndrome’, and 
it has a huge negative impact upon the quality of life (QoL) of the patients [168, 194, 195]. It 
has been suggested that partners and carers of men receiving ADT with LHRHa are also 
affected and often experience more distress than the patients themselves [196]. 
 
 
Figure 15 ADT toxicities due to reduction in sex hormone levels 
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ADT with LHRHa delivers up to a 95% reduction in serum testosterone levels, which 
in turn results in suppression of oestrogen (by about 80%) as testosterone is the substrate for 
the enzyme aromatase which converts testosterone into oestradiol [6, 164, 167]. This 
iatrogenic hypogonadism leads to the development of complications some of which (erectile 
dysfunction, loss of libido and decreased muscle mass) can be attributed to low testosterone 
levels while others (osteoporosis, fracture risk, hot flushes and dyslipidaemia) are thought to 
be due to the accompanying oestradiol deficiency (Figure 15) [155, 197]. 
There is a growing need to fully understand the nature, extent and impact of the 
toxicities resulting from long term contemporary ADT with LHRHa. This becomes even more 
relevant considering the widespread and increasing use of LHRHa. In North America, more 
than half a million men diagnosed with PC are on ADT with LHRHa at any given time. PC 
incidence has also risen with improvements in detection rates and overall survival rates have 
increased as well, resulting in more men than ever before being diagnosed with PC and 
receiving ADT for longer periods [198]. This has a multiplicative effect on the toxicity burden 
of ADT with LHRHa. The current UK costs for treating PC and its treatment-related toxicities 
exceed £100 million per year, with the total annual global expenditure estimated to be more 
than £2 billion [199]. 
 
1.7.6.8.1 Cognitive Impairment 
Several studies using neuropsychological assessments done over the last decade or 
so have linked ADT to cognitive impairment. One of the first studies examining cognitive 
function randomised men with advanced PC (n=82) to receive active treatment with LHRHa / 
anti-androgen or conservative management. Cognitive assessments were conducted at 
baseline and 6 months and ADT was shown to be associated with impairments in memory, 
attention and executive functions [200]. Men undergoing ADT have also been shown to have 
slower processing speed and diminished verbal memory (immediate and delayed) as 
compared to age matched healthy controls [201]. In a small qualitative pilot study, men 
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receiving ADT following radical treatment for localised PC were surveyed for cognitive 
problems. Results from the study showed that 8 of the 11 men reported decreases in attention, 
verbal fluency, executive functions, memory and information processing (particularly visual 
information) [202].  
A meta-analysis of 9 studies assessing cognitive function in patients receiving ADT for 
PC revealed that half of the men showed decline in at least one cognitive domain following 
ADT for 6 to 9 months. Executive functions and visuospatial abilities were the domains 
affected commonly [203]. A recent review of 11 clinical studies on the cognitive effects of ADT 
suggested a possible deleterious influence of ADT on cognitive domains including spatial 
memory and verbal memory [204]. A recent study compared cognitive performance in patients 
receiving ADT for PC (n=58) with age and education-matched PC patients treated with RP for 
localised disease (n=84) and healthy men (n=88). Groups did not differ in cognitive scores at 
baseline. Men on ADT showed higher rates of cognitive impairment at 6 months and one year 
after starting ADT compared to the two control groups. Exploratory genotyping done on 
samples obtained at baseline revealed association of guanine nucleotide binding protein (G 
protein), beta polypeptide 3 (GNB3) single-nucleotide polymorphism (SNP) rs1047776 with 
impaired cognitive performance in ADT recipients [205]. Another recent cross-sectional study 
showed decreased performance on cognitive tests of attention, memory and information 
processing in patients who received ADT for PC (n=33) as compared to patients who did not 
receive ADT (n=32) as well as age- and education-matched healthy controls (n=35) [206]. 
A few studies have yielded contradictory results. In one such study, lower than 
expected cognitive performance was seen among hormone naïve patients with PC who were 
to start ADT (n=32), suggesting a need to assess cognitive function in such men before 
starting ADT. However, no change in cognitive function was seen in those men after 6 months 
of ADT [207]. A prospective study assessing cognitive function in men (n=25) on ADT 
(neoadjuvant and adjuvant to radical RT) for 12 months showed improvement in measures of 
memory and no cognitive decline [208] One study compared cognitive performance in men 
with non-metastatic PC starting ADT (n=77) with demographically matched patients with PC 
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not undergoing ADT (n=82) and healthy controls (n=82). Cognitive assessments were done 
at baseline, 6 months and one year. Results from the study showed no consistent evidence of 
cognitive decline in ADT recipients over a period of one year as compared to the other two 
groups (P >0.05) but the type of ADT was not specified [209].  
These conflicting findings suggest a need for continued evaluation of the impact of 
ADT on cognitive function. Brain imaging studies have recently been employed to investigate 
this further. In one such study, functional MRI (fMRI) was performed using a test of visuospatial 
memory on patients with PC (n=5) at baseline and 9 months after starting ADT and 
comparison was made with healthy controls (n=7). Results showed decreased task related 
blood oxygen level dependent (BOLD) activation from baseline in the parieto-occipital region 
of ADT users [210]. Another longitudinal fMRI study compared ADT users (n=15) with non-
exposed controls (n=15). Results showed reduced BOLD activation in medial pre-frontal 
cortex on a test of cognitive control in ADT users after 6 months of treatment as compared to 
controls [211]. One study using structural MRI in PC patients receiving ADT (n=12) and non-
users (n=12) revealed decreased cortical gray matter volumes in ADT users after 6 months of 
ADT [212].  
 
1.7.6.8.2 Skeletal morbidity 
The iatrogenic hypogonadism as a consequence of present day ADT with LHRHa 
shifts the balance between osteoblast and osteoclast activity toward bone resorption, leading 
to reduction in bone mass, osteoporosis and heightened fracture risk [48, 213]. The 
detrimental effects of ADT on bone health are now widely recognised and this skeletal 
morbidity is becoming an important clinical concern in PC treatment [214-216]. The use of 
anti-resorptive agents (bisphosphonates, denusomab, toremifene) has recently been shown 
to impart osteoprotective benefit in patients undergoing ADT for PC [217-223]. 
Bisphosphonates (pamidronate, alendronate, zoledronic acid) prevent resorption of bone 
matrix by osteoclasts. Denosumab is a monoclonal anti-RANKL antibody that inhibits 
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RANK/RANKL signalling thus impairing osteoclastogenesis. Toremifene, a selective SERM, 
offsets the effects of ADT on bone as a result of lack of oestrogen [224, 225]. 
Several studies have looked at the impact of ADT on skeletal health, mostly using BMD 
and T-scores as measures of bone loss. BMD, the current gold standard for fracture risk 
prediction, refers to the bone mass per unit area while T-score is the comparison of the BMD 
value of a subject to that of a young healthy adult. A decline in BMD of 2-3% has been reported 
after initiation of LHRHa treatment for PC and this bone loss predisposes to fractures [226].  
A cross-sectional study comparing men receiving ADT for non-metastatic PC (n=133), 
hormone-naïve patients (n=43) and healthy controls (n=170) showed lowered BMD in ADT 
users than non-users. More than two-thirds of the patients on ADT were osteopaenic (T-score 
between -1 to -2.5) or osteoporotic (T-score less than -2.5) [227]. In a Canadian study of 
patients receiving ADT (n=395) with a mean follow-up of five and a half years, 23% of the 
patients became osteoporotic and 7% developed fractures. The duration of ADT was also 
associated with both osteoporosis and fractures [228]. Another study of patients with non-
metastatic PC showed a higher prevalence of osteoporosis according to the duration of ADT. 
Osteoporosis rate was 35% in hormone-naive patients as compared to 80% in men receiving 
ADT for 10 years or longer [229]. A population based cohort study of patients with PC (n=961) 
showed that men receiving long term ADT had higher rates of fracture than men receiving 
short term ADT and untreated men [230]. A Swedish study showed an increased mortality risk 
following a hip fracture in patients who underwent ADT for PC as compared to patients who 
did not receive ADT [231]. A recent large study of Chinese patients with newly diagnosed PC 
(n=17359) linked ADT to a high fracture risk and the increased risk was associated with the 
number of LHRHa doses given in the first year following PC diagnosis [232].  
A study of men diagnosed with PC (n=50,613) from the Surveillance, Epidemiology 
and End Results (SEER) - Medicare database showed ADT to be associated with an 
increased risk of fracture. 19% of the ADT recipients had a fracture, as compared with 12% 
percent of those who did not receive ADT (p<0.001). The number of doses of LHRHa received 
during the first year of treatment was also associated with fracture risk [233]. A recent study 
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of patients with localised PC (n=75,994) using the SEER - Medicare database showed that 
men assessed to have high baseline risk of skeletal complications had higher probability of 
receiving ADT than those with low risk (52.1 % versus 38.2 %; p<0.001). During the 12-year 
follow-up, nearly two-thirds of the patients with high fracture risk and one-third with low risk 
experienced at least one fracture after ADT, resulting in a 38% higher mortality risk [234]. 
A few studies utilising bone biomarkers have demonstrated negative skeletal changes 
following ADT for PC. One such study measured serum levels of bone alkaline phosphatase 
(BALP), a marker of osteoblast activity, in patients with non-metastatic PC receiving CAB 
(n=35).  Comparison was made with patients undergoing RP for localised disease (n=36). 
Serum BALP levels were measured at baseline and annually for five years. The pre-treatment 
levels in both groups were similar but increased ( > 60%) in the CAB group after 5 years with 
sharp rise ( > 30%) seen at year 1 assessment [235]. Another cross-sectional study compared 
serum levels of BALP and N-terminal telopeptide of type I collagen (NTX), a marker of 
osteoclast activity, in hormone-naïve patients with nonmetastatic PC (n=20), patients with 
nonmetastatic disease receiving ADT (n=19) and patients with metastasic disease undergoing 
ADT (n=28). Men on ADT were shown to have elevated BALP and NTX levels as compared 
to hormone-naïve men (P < 0.01). Higher BALP levels were seen in patients on ADT for 
metastatic PC as compared to men on ADT for nonmetastatic disease (P = 0.01) but serum 
NTX levels were similar (P = 0.33) [236].  
Novel imaging techniques have also been used to examine ADT induced skeletal 
changes. Using high-resolution peripheral CT, a prospective observational study 
demonstrated microstructural deterioration in distal radius and tibia of men with non-metastatic 
PC (n=26) after 12 months ADT [237]. High-resolution micro-MRI imaging (HR-MRI) has also 
shown vertebral microarchitectural decay in patients receiving ADT [238]. 
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1.7.6.8.3 Sexual dysfunction 
Sexual dysfunction and inactivity are common in PC patients on ADT with up to 90% 
of the patients reporting sexual side effects. This decline in sexual function and activity is a 
consequence of not only the sexual issues such as diminished libido, loss of sexual fantasies 
and erectile problems but adverse emotional and physical changes (decreased strength, 
fatigue, adiposity) also contribute to it [239, 240].  
Sexual and vitality measures of health-related QoL (HRQoL), assessed using the 
validated PC specific instrument ‘Expanded Prostate Cancer Index Composite’ (EPIC), have 
been shown to be impaired in patients receiving neo-adjuvant ADT for localised PC before 
starting radical RT [241]. A recent study examined the effects of ADT on sexual function and 
sexual bother in patients (n=80) undergoing ADT for advanced PC. Findings revealed a high 
prevalence of sexual problems in these men. Higher sexual bother was associated with 
younger age and earlier phase of treatment [242]. Another recent study retrospectively 
compared ADT users who reported sexual activity with sexually inactive men to identify factors 
causing sexual dysfunction in men undergoing ADT for PC. Results showed sexual activity to 
be related to maintenance of quadriceps muscle strength and overall health, suggesting 
potential beneficial impact of exercise on ADT induced sexual problems [243]. 
 
1.7.6.8.4 Patient-partner relations 
 ADT negatively impacts upon intimacy and patient-partner relationships. Following a 
PC diagnosis, the couple dynamics change to that of a patient and carer. ADT further 
compromises dyadic relationships due to its adverse effects on patient’s sexuality, vitality and 
psychological health [240]. In a small interview based study of men receiving ADT for PC 
(n=15), nearly half of the treated men were shown to experience an erosion of spousal 
relations which was not only limited to intimate sexual contact but also affected social 
interaction [244].  
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1.7.6.8.5 Cardiovascular complications 
The relationship between ADT use and CVS complications appears to be complex as 
studies examining impact of ADT on CVS have yielded conflicting results. Previously, an 
observational study suggested that men receiving ADT with LHRHa were at an increased risk 
of CVD, myocardial infarction (MI) and sudden death [245]. However, a randomised trial of 
patients with PC (n=945, 9 years follow-up) comparing RT with adjuvant LHRHa to RT alone 
showed no difference in the rates of CVS events between the two groups (8.4% vs. 11.4%, 
p=0.17). Analysis of pooled data from 8 randomised trials showed no difference in 
cardiovascular mortality between ADT users and non-users (11% vs. 11.2%, p=0.41) [246].  
Results from a pooled analysis of 6 randomised studies comparing ADT with LHRHa 
to degarelix (LHRH antagonist) showed LHRHa to be associated with a higher risk of CVS 
events in men having pre-existing CVD (p <0.002) [247]. A recent meta-analysis of 6 studies 
has also shown LHRHa to be associated with increased CVS morbidity and mortality [248]. 
Results from a study of Swedish men with PC on ADT have shown LHRHa to be associated 
with an increased risk of CVD, with highest risk during the first 6 months of initiation of therapy 
in patients with a prior history of CVD [249]. A recent large population-based cohort study of 
men with newly diagnosed PC (n=21,729) showed current use of ADT to be associated with 
an 84% higher risk of venous thromboembolism [250]. Careful monitoring for CVS health 
needs to be exercised in patients receiving ADT with LHRHa, particularly in high risk men till 
future findings clarify the role of ADT in development of CVS complications [251]. 
 
1.7.6.8.6 Physical changes 
ADT with LHRHa leads to physical changes including adiposity, sarcopaenia and 
weight gain [252, 253]. Diminution of muscle mass and excessive weight gain also contribute 
to fatigue which affects 50% of men on ADT [254]. A prospective study of men receiving ADT 
for PC (n=252) measured lean body mass (LBM) using whole body dual energy x-ray 
absorptiometry (DEXA) at baseline and then annually for three years.  Findings showed a 
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progressive decline in LBM from baseline (1% decrease at year 1; p<0.01; 2.1% decrease at 
year 2, p<0.001; 2.4% decrease at year 3, p<0.001) [255].  A longitudinal study of men 
receiving ADT after RP (n=132) showed that every 2 of 3 men studied gained weight following 
ADT and the weight gain occurred in the first year of treatment [256]. 
 
1.7.6.8.7 Metabolic syndrome 
ADT with LHRHa has been linked to development of metabolic complications including 
dyslipidemia, insulin resistance and diabetes [245, 257, 258]. Weight gain, obesity and 
adiposity are also seen with ADT [258, 259]. All these features constitute metabolic syndrome 
which is seen in half of the men receiving ADT. Metabolic syndrome predisposes these men 
receiving ADT for PC to an increased risk of CVS complications [260].  
 
1.7.6.8.8 Anaemia 
 The development of normochromic normocytic anaemia is a commonly encountered 
hematological consequence of ADT which may also be one of the main factors causing fatigue 
in these patients. Reduction in the stimulatory effect of testosterone on the differentiation of 
erythroid stem cells in the bone marrow and renal erythropoietin production have been 
proposed as possible mechanisms of ADT associated anaemia [261, 262]. In a study of 
patients with metastatic PC (n=135), haemoglobin (Hb) levels were significantly reduced after 
3 to 9 months of LHRHa therapy as compared to baseline (Mean Hb. decline -1.66 g/dL, 
p<0.001) [263]. A drop in Hb. levels following 3 months of ADT has been associated with 
reduced overall and progression-free survival [264].  
 
1.7.6.8.9 Vasomotor symptoms  
Vasomotor symptoms including hot flushes and night sweats are frequently reported 
by patients undergoing ADT for PC [188, 192, 193, 265]. Sharp decline in circulating sex 
hormone levels brought about by ADT is thought to induce re-setting of the thermostat in pre-
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optic area of hypothalamus to a lower point, which causes hyperactivation of peripheral 
thermoregulatory mechanisms resulting in development of hot flushes and night sweats [168]. 
Findings from a questionnaire based study showed that more than 90% of men experience 
female climacteric-like side effects such as hot flushes and night sweats following ADT with 
LHRHa [266]. LHRHa cause vasomotor symptoms shortly after initiation of therapy. These 
symptoms persist beyond cessation of treatment in some men and are a cause of substantial 
psychological distress [265].  
 
1.7.6.8.10 Sleep disturbances 
Sleep problems occur commonly in men undergoing ADT for PC [266, 267]. In one 
study using wrist actigraphy and subjective measures for assessment of sleep pattern, 
patients receiving ADT (n=60) were shown to have reduced and poor night time sleep, and 
increased sleepiness during the day [268]. A recent questionnaire based study showed higher 
insomnia scores in patients receiving adjuvant ADT with RT compared to RT alone. Night 
sweats seemed to be associated with sleep disturbance [269].  
 
1.7.6.8.11 Renal problems 
Acute renal problems in patients undergoing ADT have recently been highlighted. 
Findings from an observational study of patients with newly diagnosed non-metastatic PC 
suggest ADT use to be associated with an increased risk of acute renal injury. In this study, 
232 new cases of acute renal injury were identified from a cohort of men treated with ADT 
(n=10,250) during a mean follow-up of 4.1 years [270].  Results from another large 
retrospective study of patients with non-metastatic PC (n=69,292) have also linked 
administration of ADT to an increased risk of acute kidney injury. The 10 year rates of acute 
kidney injury were shown to be higher in men receiving LHRHa than bilateral orchidectomy 
(31% vs. 26%, p< 0.001) [271]. 
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1.7.6.9 Parenteral oestrogen as androgen deprivation therapy 
Oral oestrogen DES was previously used as ADT but its use was curtailed owing to 
concerns over CVS and thromboembolic toxicity [160]. It is now evident that oral administration 
exposes the liver to very high concentrations of oestrogen via portal circulation. This first pass 
through the liver upregulates hepatic synthesis of pro-coagulant proteins and induces a 
hypercoagulable state, thereby escalating the risk of serious thromboembolic and CVS events 
such as myocardial infarction and stroke [272].  
Parenteral oestrogen administration (intramuscular, transdermal) not only results in 
central suppression of androgen production but also mitigates the thromboembolic 
consequences of oral therapy by avoiding first-pass effect through the liver. Castrate levels of 
testosterone for PC growth arrest can be achieved by this strategy, with little effect on 
haemostatic profile [273-275]. By replacing endogenous oestrogen lost otherwise as a result 
of contemporary ADT with LHRHa, parenteral oestrogen may potentially mitigate the 
oestrogen deficiency related serious adverse events such as osteoporosis [276, 277]. 
Previous data from studies using parenteral oestrogen as ADT for PC have highlighted the 
bone-sparing potential of this treatment. A study of patients with advanced PC (n=20) treated 
with transdermal oestradiol as primary ADT reported increases in total hip and lumbar spine 
BMD after a year of starting therapy [278]. In another study of men with advanced PC (n=910) 
with 9 years follow-up, none of the patients on intramuscular oestrogen (polyoestradiol 
phosphate) developed any serious skeletal event compared to 18 on CAB [275]. 
The PATCH (Prostate Adenocarcinoma TransCutaneous Hormones) study is an 
ongoing randomised clinical trial, now in Phase III, comparing transdermal oestradiol with 
LHRHa in locally advanced and metastatic PC. In the first stage (n=254) of the phase II study, 
similar rates of significant CVS events (the primary outcome) were reported in both trial arms. 
Serum glucose and cholesterol profiles were also shown to be more favourable in the 
oestradiol group than in the LHRHa group (Table 7) [279]. Results from a sub-study of the 
phase II trial evaluating bone health showed decreased lumbar spine BMD with LHRHa 
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compared to baseline while it increased with oestrogen patches (Table 6) [280]. Parenteral 
oestrogen appears to be an effective and safe therapeutic option for the treatment of PC. 
Future data from trials such as PATCH will contribute to the evidence-base required to 
establish parenteral oestrogen as an alternative to contemporary ADT with LHRHa.  
 
Table 7 Comparison of CVS, metabolic and skeletal parameters from the PATCH study [279, 
280] 
Outcomes 
 
LHRHa Transdermal oestradiol  
Proportion of patients with CVS 
events (Median follow-up 19 
months) 
7.1% 
(n=84) 
10.1% 
(n=169) 
Proportion of patients with 
castrate testosterone (≤1.7 
nmol/L)  at 3 months 
93% 
(n=75) 
92% 
(n=121) 
Percentage change in fasting 
glucose at 12 months from 
baseline 
+5.5% 
(n=54) 
-2.4% 
(n=95) 
p-value 0.004 
Percentage change in fasting 
cholesterol at 12 months from 
baseline 
+4.1% 
(n=55) 
-3.3% 
(n=101) 
p-value <0.0001 
Percentage change in lumbar 
spine BMD at 12 months from 
baseline 
-2.11% 
(n=21) 
+6.43% 
(n=39) 
p-value <0.001 
Percentage change in lumbar 
spine BMD at 24 months from 
baseline 
-6.09%, 
(n=10) 
+4.58%, 
(n=20) 
p-value <0.001 
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2. Statement of research problem 
 
This project aimed to define the influence of alterations in sex hormones on certain 
important aspects of systemic function in a population of patients with PC receiving ADT. 
Usually achieved using LHRHa, contemporary ADT causes marked suppression of sex 
hormones (both androgens and oestrogens) resulting in ‘castration syndrome’, a constellation 
of adverse events including skeletal complications, cognitive problems and potential 
psychosocial issues arising from changes in odour signalling which are some of the least well 
studied yet important factors affecting morbidity and QoL of patients undergoing therapeutic 
sex steroid changes. 
 
2.1 Scientific rationale 
2.1.1 Cognitive study 
Cognitive abilities differ between males and females [210], possibly due to the varying 
sex hormone levels and their receptor distribution in brain. Studies in menopausal women 
suggest that women who use HRT have better cognitive skills and memory compared with 
age-matched non-users [38, 42]. Cognitive decline in men has higher prevalence in the elderly 
and testosterone replacement in older men has been shown to improve cognitive functioning 
[281, 282]. At present, work on potentially deleterious cognitive effects of reduced sex 
hormone levels on cognitive function in men (such as that seen with ADT for PC) is 
inconsistent, limited to a few studies as compared to work in females, generally poorly 
controlled and uses vastly differing individual, often non-validated and subjective approaches 
which make interpretation difficult. It is not even firmly established that cognitive decline is 
always a consequence of ADT [203, 204]. Further work is required to objectively quantify 
cognitive dysfunction due to ADT, understand the mechanism, predict which patients will be 
affected and determine ways of reducing this side effect.  
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Establishing the presence of pathophysiology in ADT induced cognitive dysfunction 
first is important due to the lack of understanding of the underlying mechanism. A plausible 
scientific approach in this regard appears to be the use of the brain’s immunological response 
to pathology using a PET imaging ligand for activated microglia. Brain microglia have been 
demonstrated to be highly responsive to brain injury and are rapidly activated in an attempt to 
envelope/ contain the focal pathology. When activated, the microglia express an 18 kDa 
protein called TSPO, formerly known as the peripheral benzodiazepine receptor (PBR), which 
has been proposed as a neuroinflammatory marker [283]. PET imaging ligands have been 
developed for TSPO and used successfully for researching a range of brain disorders such as 
neurodegenerative diseases, stroke, physical trauma and multiple sclerosis [284]. One such 
radio-ligand targeting TSPO is [11C]PBR28 (Carbon-11 Peripheral Benzodiazepine Receptor 
Ligand) which has a 20-minute half-life, thus making it feasible to perform PET without concern 
for residual radioactivity [285]. Although such imaging does not provide mechanistic 
information of the underlying pathology, except for neuroinflammation, it does offer a generic 
sensitive biomarker for demonstrating the presence of an on-going active pathology.  
The non-invasive MRI technique has recently been used for assessing brain structure 
and function in patients receiving ADT for PC [210-212]. To better gauge the cognitive 
changes and pathology in settings of altered sex hormones, further studies employing imaging 
modalities and specific validated neuropsychological assessments are warranted. 
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2.1.2 Bone study 
 Osteoporosis, a disease characterised by compromised bone strength and increased 
risk of fractures, is a serious public health concern and estimates suggest that over 200 million 
people are affected worldwide [286]. A quarter of all men over the age of 50 years are likely 
to suffer an osteoporotic fracture at some point in their lifetime and the mortality risk one year 
post hip fracture is double in men as compared to women [287, 288]. Long-term glucocorticoid 
therapy, chronic alcoholism and hypogonadism account for nearly 50% of all cases of 
osteoporosis in men. ADT for PC is a major cause of iatrogenic male hypogonadism [226]. 
PC has a strong tendency toward bone metastases which disrupt skeletal 
homeostasis, resulting in elevated serum levels of biochemical markers of bone metabolism 
(e.g. NTX, alkaline phosphatase; ALP).  These markers are associated with higher mortality 
and fracture rates in patients with metastatic disease [286, 287]. ADT induced decline in 
circulating sex hormone levels accelerates bone turnover, a process characterised by 
increased bone resorption and formation, which leads to a rise in the levels of biomarkers of 
osteoblastic and osteolytic activity [235, 236]. ALP is one such marker which is derived from 
several sources including liver, bone, kidneys, spleen, intestines and placenta. The two 
predominant serum isoforms of ALP are of hepatic and skeletal origin [289]. Serum BALP, the 
bone-specific isoform, is a measure of osteoblastic activity that can potentially be utilised as 
an early indicator of development of osteoporosis and associated fragility fractures [290]. In 
postmenopausal women, serum BALP is associated with fracture risk irrespective of BMD 
[291].  
Progressive increase in the prevalence of osteoporosis has been reported in patients 
undergoing ADT, reaching up to 80% after 10 years of ADT [229]. The negative skeletal effects 
of contemporary ADT with LHRHa are increasingly recognised and an important consideration 
in overall management of these men [214, 233, 234]. At present, osteoporosis and associated 
fracture risk are mostly gauged clinically in terms of BMD assessment performed by DEXA 
[238, 292]. BMD refers to the bone mass per unit area and is employed as an indirect indicator 
83 
 
of fracture risk. However, BMD measurements are rarely employed clinically in patients 
receiving ADT; of 28,960 men with loco-regional PC receiving ADT for more than 1 year, only 
10% had BMD testing during an 18-month period, starting from 6 months before beginning 
ADT [293]. 
Importantly, BMD does not reflect bone quality which is an integration of several 
features influencing skeletal resistance to fractures. Bone quality depends upon material and 
structural factors including but not limited to mineralisation, quality of collagen, rate of bone 
turnover, cortical geometry and trabecular micro-architecture (including trabecular number, 
thickness, orientation and connectivity) [294, 295]. The ability of bone to resist fracture 
depends not only on the amount of bone (as measured at present by BMD testing) but also 
the spatial distribution of bone mass and the intrinsic properties of the materials that constitute 
bone which come under the wide ranging concept of bone quality. Bone strength reflects the 
combination of bone mass and bone quality [296]. BMD testing only measures the areal bone 
mass and does not capture any structural information because images are two dimensional 
(2D). Thus BMD is not an adequate surrogate marker of bone strength; it only explains about 
50% of ex vivo strength [297]. 
Development of improved measures of bone strength is required for identification and 
assessment of rapidly occurring skeletal changes seen with therapeutic interventions like ADT 
as well as other pathological or age-related deterioration in bone health. Three dimensional 
(3D) imaging techniques including micro-computed tomography (micro-CT), are employed for 
assessing bone strength ex-vivo but are of limited clinical use at present owing to radiation 
hazards as well as technical issues, high costs and accessibility [298, 299]. Micro-CT enables 
ex vivo evaluation of various parameters such as volumetric bone mass (expressed as bone 
volume fraction ‘BVF’) which has been identified as a strong determinant of bone strength (R2 
> 0.8) [300, 301]. 
Low-resolution clinical-CT is a non-invasive and accessible imaging technique 
available to most hospitals. 3D measures such as BVF derived from clinical-CT scans are 
potentially a useful option for estimating bone strength. Clinical-CT derived measures of hip 
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morphology may be especially useful because the hip (a key fracture site in PC patients 
associated with high mortality) is routinely imaged as part of a pelvic CT scan for staging PC 
and planning radiation therapy, potentially offering low cost, easily accessible and safe 
technology for predicting bone strength. Bone markers reveal variations in bone homeostasis 
and early changes in bone markers such as BALP, which precede measurable changes in 
bone strength, need to be studied in the context of ADT for PC. The importance of measuring 
bone markers for monitoring early response to treatment with anti-resorptive or bone forming 
agents has been highlighted in some studies [302-304]. Such measurements can potentially 
allow for non-invasive and convenient monitoring of bone health in patients receiving ADT for 
PC and help clinicians to target CT based skeletal assessments at high-risk patients for 
diagnosing, treating and/or preventing osteoporosis and fractures. 
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2.1.3 Odour study 
Every individual has a unique body odour that can be discerned by others. Axillary 
odour, readily identifiable due to its pungent nature, is generally referred to as body odour 
[73]. Body odour is affected by several factors and gender is one of the major ones. Axillary 
secretions are known to contain various odoriferous volatile chemicals, some of which are 
metabolic derivatives of sex hormones [74]. Body odour is thought to provide cues about a 
potential sexual partner’s health, reproductive status and genetic quality. Body odour is 
considered a signal of physical and sexual appeal in humans and it has also been associated 
with masculinity and dominance [65-67]. Odour of men has been shown to change with age 
[72] but it has not yet been studied whether that is due to age-related variations in their sex 
hormone profile.  
Sexual activity has been shown to decline considerably in PC patients on ADT with 
LHRHa. This sexual inactivity is a consequence of low testosterone, diminished libido, 
decreased physical strength and erectile dysfunction [239, 240]. Loss of masculine traits in 
PC patients negatively impacts their social and sexual life. These side effects of ADT also 
affect the intimate partners of patients and it has been indicated that partners often experience 
more distress than the patients themselves [196]. Results from an earlier study suggested that 
nearly half of all men on ADT experienced an erosion of dyadic relations and causal evidence 
for these relationship changes should be sought in factors affected by treatment [244]. Body 
odour changes following ADT have not been documented but they may have a significant 
psychosocial impact on the QoL of patients with PC and their partners. 
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2.2 Hypotheses 
 Increased cerebral binding of [11C]PBR28 is seen on PET imaging in patients with PC 
having LHRHa induced cognitive impairment 
 PC patients reporting cognitive problems since starting ADT with LHRHa show 
reduced cognitive performance on neuropsychological testing using specific validated 
instruments. 
 BVF metrics obtained from CT scans provide improved measures of bone mass and 
strength. 
 ADT with LHRHa results in elevation of serum BALP levels in patients at three months 
following commencement of treatment. 
 ADT with LHRHa induces perceptible changes in body odour of PC patients PC after 
three months of therapy.  
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2.3 Objectives 
 To demonstrate, using a PET imaging biomarker of activated microglia (TSPO), the 
presence of global and regional pathological changes in the brain that relate to LHRHa 
induced cognitive impairment in patients with PC 
 To objectively determine cognitive changes in patients with PC undergoing ADT with 
LHRHa using validated paper-based neuropsychological assessments and 
computerised cognitive testing 
 To provide insight into possible mechanisms of LHRHa induced cognitive decline i.e. 
association of a specific cognitive dysfunction with regional neuroinflammatory 
response. 
 To develop a method for measuring BVF of the femoral head trabecular bone at a low 
resolution (550µm voxel size; i.e. comparable to clinical-CT resolution) 
 To validate the devised BVF metrics against high-resolution (30µm voxel size) micro-
CT data  
 To determine whether the BVF metrics calculated at low resolution relate to bone 
strength. 
 To determine early changes in serum BALP following ADT with LHRHa 
 To relate serum BALP changes in patients undergoing ADT to serum sex hormone 
concentrations 
 To determine changes in odour signalling following ADT with LHRHa 
 To relate the odour changes in patients on ADT with LHRHa to the serum levels of sex 
hormones 
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3. Research methodology 
 
3.1 Cognitive Study 
 
3.1.1 Regulatory approvals 
 The study received ethical approval from the Queen Square Research Ethics 
Committee (REC), London (Ref 13/LO/0731). Local research and development (R&D) 
approval and sponsorship was granted by the Joint Research Compliance Office (JRCO) at 
Imperial College Healthcare NHS Trust (ICHT), London (JRCO Ref 13HH0558). Insurance 
cover was provided by Imperial College London's Arthur J. Gallagher negligent and non-
negligent harm policy (B1262FI0103012). The study received peer review certification from 
Imperial College London Peer Review Committee (Ref 0057/IC0031). The study protocol was 
subsequently amended twice to attain the final form and each amendment was duly approved 
by the REC and JRCO (Appendix II). 
 
3.1.2 Study design 
A cross-sectional analytical study design was employed for this study to compare 
quantitative [11C]PBR28 PET imaging in patients with clinically noticeable ADT associated 
cognitive impairment with an age and treatment matched cohort with no such observable 
change. Neuropsychology testing was done to assess cognitive function. 
 
3.1.3 Sampling 
Non-probability consecutive sampling technique was used for recruiting subjects in this 
study. All accessible subjects fulfilling the eligibility criteria were approached as they presented 
to the clinics for potential enrolment in the study. 
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3.1.4 Study population 
Target population included patients with PC receiving LHRHa for either newly 
diagnosed advanced disease, as adjuvant or neoadjuvant to RT or for biochemical relapse 
with a rising PSA following definitive treatment with RP or RT (without adjuvant or neoadjuvant 
LHRHa).  
 
3.1.5 Recruitment 
Patients were recruited from the uro-oncology follow-up clinics of ICHT. The potential 
participants were identified and approached in the clinics. Written informed consent was 
obtained before participants entered into the study. When obtaining consent from a patient, 
the study and the information sheet were introduced in full by the researcher. Patients were 
allowed at least 24 hours to consider participation but they were free to take as long as they 
wished before making a decision and then consent taken. Consent forms, regulatory approval 
documents and non-anonymised patient data were kept at secure ICHT location.  
 As advised by the REC, the participants were asked about any previous radiotherapy 
and scans they have had in the last year and their medical notes were also reviewed for the 
same to ensure the participants did not get excessive radiation exposure. The radiation dose 
from this study was less than 3mSv which is a little more than the average annual background 
radiation dose of 2.5mSv in the UK. The radiation exposure from a CT scan of the chest, 
abdomen and pelvis on the other hand is of the magnitude of 25 mSv. UK residents in general 
have a 1 in 4 risk of developing fatal cancer in their lifetime. The additional risk of developing 
fatal cancer as a result of the radiation exposure from this study was about 1 in 6500 for 
healthy middle aged adults, which would change the estimated risk of developing fatal cancer 
from approximately 1 in 4, to 1 in 3.998. Thus, the radiation dose in this study had a negligible 
impact on the risk of future cancer development.  
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The eligibility criteria employed for this study is given below: 
 
3.1.5.1 Inclusion Criteria 
 Patients between the ages 50 to 80 years. 
 Currently on ADT with LHRHa for at least 3 months and up to a year. 
 Able to give written informed consent. 
 Able to lie still for up to 90 minutes for a PET scan. 
 Not claustrophobic and so able to undergo an MRI scan. 
 
3.1.5.2 Exclusion Criteria 
 Known history of neurodegenerative disorders and associated dementia or delirium. 
 Known history of neuropsychiatric conditions, stroke or traumatic brain injury (TBI). 
 Clinically assessed as having MCI prior to starting ADT with LHRHa. 
 History of receiving ADT with LHRHa prior to current treatment 
 A medical survival prognosis of less than 3 months. 
 Patients who were claustrophobic. 
 Patients having any metal implanted in their body e.g. heart pacemaker, cochlear 
implant or any other electronic device. 
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3.1.6 Study procedures 
 The study procedures were conducted in two stages (Figure 16). Details of each step 
are described below.  
 
Figure 16 Stage wise conduct of study procedures for the cognitive study 
 
3.1.6.1 Stage 1 
All the recruited participants underwent Stage 1 procedures which included detailed 
clinical history, mini-mental state examination (MMSE), Wechsler’s test of adult reading 
(WTAR), blood test for determining TSPO genetic polymorphism and detailed 
neuropsychological assessment (paper-based and computerised). All stage 1 procedures 
were carried out at the uro-oncology clinics of ICHT on routine follow-up visits. For 
neuropsychological testing, it was ensured that each participant was wearing his routine 
hearing and/or visual aid if any, as testing required adequate hearing and vision. 
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3.1.6.1.1 Clinical history 
Recruited patients were grouped into two based on a detailed clinical history taken by 
the researcher. History was taken from the patient and/or their partners/carers where 
applicable. The study group comprised of patients who reported or were clinically assessed to 
have noticeable impairment in cognitive ability since starting on treatment with LHRHa. The 
control group comprised of patients who did not notice and were not clinically assessed to 
have any change in cognition. 
 
3.1.6.1.2 Mini-mental state examination 
MMSE is a short clinical screening tool (11 items, maximum score 30) that tests 
cognitive areas including orientation, registration, attention, calculation, recall, and language 
(Appendix III) [305]. MMSE was used in this study to substantiate clinical history and screen 
out patients with overt cognitive dysfunction that might possibly be related to a pathology or 
event other than LHRHa. Patients with MMSE score of 24 or above were included. 
 
3.1.6.1.3 Wechsler’s test of adult reading 
 WTAR is a neuropsychological test used to estimate the pre-morbid intelligence 
quotient (IQ) [306]. WTAR was administered to the study participants to provide a baseline 
measure of their intellectual capacity before starting ADT with LHRHa. A list of fifty words was 
presented to the patient. The list contained irregularly spelled words with an increasing 
complexity (Appendix III). The participants were asked to pronounce each word aloud. One 
mark was given for each word pronounced correctly for a maximum raw score of 50. The raw 
score was then standardised by age using a standardisation chart.  
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3.1.6.1.4 TSPO genetic polymorphism testing 
For determining the TSPO genetic polymorphism, 5ml venous blood was collected 
from each participant in ethylenediaminetetraacetic acid (EDTA) vacutainer tubes (purple 
cap). The sample was sent for TSPO mutation analysis to Dr. Letizia Foroni at the Imperial 
Molecular Pathology Laboratory, Hammersmith hospital within 4 hours of collection. A 
standard analysis was requested with a turnaround time of 10 working days.  
 
Rationale, analysis and interpretation 
TSPO genotype at position 439 (SNP rs6971) predicts the binding affinity of TSPO 
receptor to [11C]PBR28. For analysis, DNA was extracted from each peripheral blood sample 
using the Qiagen QIAamp DNA blood mini kit. TSPO genotyping of the SNP rs6971 was 
performed using a TaqMan allelic discrimination assay [307]. The analysis of each sample 
yielded one of the following three results: 
 
 The homozygous G variant allele; predictive of high affinity 
 The heterozygous A/G allele; predictive of medium affinity 
 The homozygous A allele; predictive of low affinity 
 
Some patients were excluded at this stage and only those participants who were 
shown to have the homozygous G variant allele (incidence in general population is 25-50%) 
which demonstrates expression of high affinity binding of the TSPO receptor to the PET 
imaging marker [11C]PBR28 proceeded to stage 2 of the study.  
 
3.1.6.1.5 Detailed neuropsychological assessment 
Cognitive functions of the study participants were assessed using a comprehensive 
battery of standard validated paper-based neuropsychological questionnaires and computer-
based tests (www2.CBSTrials.com) [308, 309].   
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3.1.6.1.5.1 Paper-based tests 
 Administering the paper-based tests took one and a half hours on average per 
participant. The individual test descriptions are given below: 
 
3.1.6.1.5.1.1 Trail making test 
 This task was used to assess cognitive processing speed and working memory [310-
312]. The task had two conditions (Appendix III). In condition A, the participants were asked 
to connect circled numbers by drawing lines in an ascending numerical sequence as quickly 
as possible without lifting the pen from the paper. In condition B, the participants were asked 
to connect circled numbers and letters in an alternating numeric and alphabetic sequence by 
drawing lines as quickly as possible without lifting the pen from the paper. The participants 
were timed as they connected the trail. Scores were reported as seconds required to complete 
each condition (higher scores meant greater impairment).  
 
3.1.6.1.5.1.2 People test 
This sub-set of the doors and people test was employed to measure associative 
learning and verbal recall memory [313]. In this task, the participants were instructed to 
remember the names of four people. The participants were then shown papers containing 
photographs of those four people with their name (forename and surname) and job written 
underneath (Appendix III). Then they were asked to recall the names. The procedure was 
repeated two more times. For each forename or surname recalled correctly, 1 mark was given 
and an extra mark was given for a correct pairing. Sum of the scores from the three trials gave 
the total score for immediate recall. The participants were asked to recall the names once 
again after 10 minutes for delayed recall. 
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3.1.6.1.5.1.3 Colour-Word interference test 
 The colour-word interference test (CWIT), taken from the Delis-Kaplan executive 
function system (D-KEFS), was used to assess executive functions including cognitive 
flexibility and processing speed [314]. The test involved four trials (Appendix III). In the ‘colour 
naming’ trial, the participants were asked to identify colours of the printed squares. In the ‘word 
reading’ trial, the participants were asked to read colour names (red, blue, green) printed in 
black ink. In the ‘inhibition’ trial, the participants were required to name the colour of the inks 
in which the words were printed and not read the printed word. In the ‘inhibition switching’ trial, 
the participants were asked do the same as they did in inhibition trial for words not in a box 
but for words inside a box, they were required to read the word and not name the colour of the 
ink. Each trial was timed and scores were reported as seconds required to complete each 
condition (higher scores meant greater impairment). 
 
3.1.6.1.5.1.4 Letter fluency 
 Letter fluency is a form of verbal fluency (ability to produce words under specific 
instructions and fixed time) which involves working memory, cognitive flexibility and strategy 
making. Letter fluency subtest of D-KEFS was used [315, 316]. The participants were asked 
to retrieve as many words as possible starting with letter F in one minute and the procedure 
was repeated with letters A and S. The participants were instructed to avoid repetition and 
names of places, people and numbers. One mark was given for each correct word and the 
sum of all gave the total score. 
 
3.1.6.1.5.1.5 Logical memory 
Logical Memory subtest of the Wechsler Memory Scale, third edition (WMS-III) was 
used as a measure of immediate and delayed verbal recall [317]. The test, involving two short 
stories, was administered as immediate and delayed trials (Appendix III). Story A was read 
out once to the participants who were then asked to recall the information as word for word as 
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possible. Story B was read out twice and after each reading, the participants were asked to 
recall the information in as much detail as possible. One mark was awarded for each specific 
information recalled. The participants were instructed to try to remember the stories. After a 
lapse of half an hour, the participants were asked to provide any information recalled from 
each of the two stories and scores were recorded again. For each story, the participants were 
also asked fifteen yes/no type questions for recognition memory and scores were recorded. 
 
3.1.6.1.5.1.6 Similarities 
This subtest of the Wechsler Abbreviated Scale of Intelligence (WASI) was used to 
measure semantic verbal reasoning ability [318]. Pairs of words were read out to the 
participants who were asked to tell how the two words in each pair were similar. Scoring was 
done according to the general scoring principles and sample responses provided in the 
manual (e.g. for the word pair ‘grapes-strawberry’, 2 marks were awarded if the response 
was ‘fruits’, 1 mark was awarded if the response was ‘sweet’ and no mark was awarded for 
an irrelevant response such as ‘minerals’).  
 
3.1.6.1.5.1.7 Matrix Reasoning 
This WASI subtest was used to assess visuospatial and non-verbal logical reasoning 
ability [318]. The participants were shown incomplete matrices and they were asked to select 
the correct response options that completed the matrices (Figure 17). Five response options 
were provided for each matrix shown. 1 mark was given for each correct response and the 
sum gave the total score. 
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Figure 17 Administered item from the matrix reasoning test 
 
3.1.6.1.5.1.8 Digit Span 
This WMS-III subtest was used for the assessment of short-term memory and attention 
span. It has two components, forward and backward digit spans [319]. Digit sequences were 
read out to the participants who were asked to recall the digits in the same sequence for 
forward and in reverse order for backward test. The sequences were presented beginning with 
a set of two trials of two digits length which increased by one digit for the next set of trials. 
Testing was stopped when the participants failed to recall correctly a set of two trials for a 
particular digit length. 1 mark was awarded for each accurate recall and the sum of the scores 
on forward and backward tests gave the total score. 
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3.1.6.1.5.2 Computer-based tests 
 
All computer-based tests were administered on a laptop computer (HP ProBook 
6570b, Intel CORE i5 processor, Windows 7) using the application CBS App V2 running on 
Adobe AIR software (Version 15.0.0.293). Administering the computer-based tests took one 
hour on average per participant. The individual test descriptions are given below. Each test 
was preceded by a set of instructions displayed on the computer screen. Verbal instructions 
and explanation were avoided to ensure consistency. 
 
3.1.6.1.5.2.1 Digit span 
This test was used to assess short-term working memory [320]. A sequence of digits 
appeared on the screen one after another and participants were asked to repeat the sequence 
by pressing the respective number keys on the keyboard (Figure 18). The number of digits in 
the subsequent trial increased or decreased by 1 subject to the participant repeating the 
sequence correctly or incorrectly. The test finished after 3 errors. 
 
 
Figure 18 Screenshot of the digit span test 
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3.1.6.1.5.2.2 Spatial span 
Spatial span task was employed for measuring short-term spatial memory [321]. 
Sixteen squares were displayed on the screen. A sub-set of the squares flashed in a random 
order and the participants were then asked to click on the squares in the same sequence in 
which they flashed (Figure 19). The test started with four flashes and with a correct response, 
the length of the following sequence increased by one flash. An incorrect response resulted 
in the length of the subsequent sequence being one flash shorter. The test finished after 3 
incorrect responses.  
 
 
Figure 19 Screenshot of the spatial span task 
 
3.1.6.1.5.2.3 Paired associates 
This task was used to assess associative memory performance [322]. In each trial, 
boxes were displayed on the screen at random positions. The boxes opened one after another 
to reveal an object which then disappeared (Figure 20). The revealed objects were then 
presented in the centre of the screen in a random sequence and the participants were asked 
to click on the respective boxes that contained them. If the participant correctly identified all 
object-box pairs in the trial, the next trial increased by 1 object-box pair and vice versa. The 
first trial started with two boxes. The test ended after 3 errors. 
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Figure 20 Screenshot of the paired associates test 
 
3.1.6.1.5.2.4 Self-Ordered search 
This test was employed to assess strategy making ability [323]. Sets of boxes were 
presented at random spots on the screen. The participants were required to search for hidden 
tokens in all the boxes by clicking on them one at a time (Figure 21). A token would not appear 
within the same box twice in a given trial. The trial ended if the participant clicked on an empty 
box twice or on a box in which a token had already been found and the subsequent trial had 
one box less to search. If the tokens were identified once in each box without any errors, the 
subsequent trial had one additional box to search. The first administered trial had four boxes. 
The test ended after 3 errors. 
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Figure 21 Screenshot of self-ordered search task 
 
3.1.6.1.5.2.5 Spatial rotation 
This task was used to measure visuospatial capacity (the ability to rotate an object in 
mind) [324]. In each trial of the task, two grids of coloured squares were presented at the same 
time with one of the grids rotated by either 90o, 180o or 360o. The grids when aligned after 
rotating in mind were either identical or different. The participants were required to indicate 
whether the grids were identical or not by clicking ‘match’ or ‘mismatch’ on the screen (Figure 
22). The trials were presented one after the other for 90 seconds and the participant was 
asked to solve as many problems within that time. The first trial contained 4 coloured squares 
in each grid. Every correct response led to an increase in the total score by the number of 
squares in the grid and the next trial had more squares. Every incorrect response led to a 
decrease in the total score by the number of squares in the grid and the following trial had 
fewer squares. 
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Figure 22 Screenshot of the spatial rotation task 
 
3.1.6.1.5.2.6 Feature Match 
This task was used to estimate attentional processing ability [325]. In each trial, two 
grids were shown on the screen each having a set of abstract shapes. The participants were 
asked to indicate whether contents in the two grids were matching or not (Figure 23). For a 
correct response, the total score increased by the number of shapes in the grid and next trial 
had more shapes. For an incorrect response, the total score decreased by the number of 
shapes in the grid and subsequent trial had fewer shapes. The first trial had two abstract 
shapes in each grid. The trials were presented for 90 seconds. 
 
 
Figure 23 Screenshot of the feature match test 
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3.1.6.1.5.2.7 Polygons 
Polygons test was used to assess visuospatial and constructional ability [305]. In each 
trial, a pair of interlocking polygons was presented on one side of the screen and a single 
polygon was displayed on the other side. The participants were required to point out if the 
single polygon exactly matched one of the overlapping polygons or not by clicking ‘match’ or 
‘mismatch’ on the screen (Figure 24). The trials were presented for 90 seconds and the 
participants could attempt as many trials as possible within that time.  
 
 
Figure 24 Screenshot of the polygons task 
 
3.1.6.1.5.2.8 Monkey span 
This task was used to assess visuospatial working memory [326]. Sets of numbered 
squares were shown simultaneously at random locations on the screen (Figure 25). The 
numbers were then removed from the squares and the participants were asked to click on the 
squares starting from number 1 onward in an ascending sequence. The first trial started with 
a set 2 numbered squares which then increased or decreased by 1 for a correct or incorrect 
response respectively. The test finished after 3 incorrect responses. 
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Figure 25 Screenshot of the monkey span test 
 
3.1.6.1.5.2.9 Double trouble 
Double trouble test, a colour-word mapping task, is devised from the colour-word test 
[327]. In each trial, one of the two words RED or BLUE was shown at the top of the screen in 
either red or blue font colour. The words RED and BLUE were also displayed at the bottom of 
the screen, again having either red or blue font colour (Figure 26). The participants were 
required to click on the word at the bottom of the screen that described the font colour of the 
word at the top of the screen. The participants were instructed to solve as many trials as 
possible within 90 seconds. The total score increased or decreased by 1 after each trial 
depending on the participant’s answer. 
 
 
Figure 26 Screenshot of the double trouble task 
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3.1.6.1.5.2.10 Verbal Reasoning 
This test was employed to assess verbal reasoning ability [328]. In each trial, two 
objects (e.g. circle and square) were displayed on the screen with a statement (e.g. square is 
bigger than circle, square is not encapsulated by circle etc.). The participants were asked to 
tell whether or not the statement accurately described the relation between the objects shown 
by clicking ‘true’ or ‘false’ on the screen (Figure 27). The participants were instructed to attempt 
as many trials as possible within 90 seconds. Total score increased by 1 for each correct 
response and decreased by 1 for each incorrect answer. 
 
 
Figure 27 Screenshot of the verbal reasoning test 
 
3.1.6.1.5.2.11 Odd one out 
This task was employed to assess deductive reasoning ability [12]. Nine cells were 
shown on the screen, each containing patterns with features (shape, colour and number of 
copies) corresponding to each other according to some rules (Figure 28). The participants 
were asked to deduce those rules in order to identify the one cell whose contents did not relate 
to those rules. Total score increased by 1 and the following trial became more complex after 
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a correct response and vice versa. The trials were presented one after the other for three 
minutes. 
 
 
Figure 28 Screenshot of the odd one out task 
 
3.1.6.1.5.2.12 Hampshire tree test 
This spatial planning task was used to measure executive function [329]. Numbered 
balls were positioned on a tree-like frame in each trial (Figure 29). The participants were 
required to reposition the balls, in as few moves as possible, in an ascending numerical order 
running from top to bottom and left to right of the frame. The trial was terminated if the 
participants made more than double the minimum number of moves required to correctly re-
arrange the balls in that trial. The participants were given three minutes to complete as many 
trials as possible. Score for each trial was calculated by subtracting the number of moves 
taken by the participant from the minimum number of moves required x2. Sum of the scores 
in each trial gave the total test score. 
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Figure 29 Screenshot of the Hampshire tree task 
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3.1.6.2 Stage 2 
Stage 2 involved PET brain imaging which was undertaken at the Imanova Centre for 
Imaging Studies, London, UK. Figure 30 describes the basic principle of PET imaging. A 
structural MRI scan was also performed on the same day for neuroanatomical interpretation 
of the PET scan. Checks were made before MRI scanning to ensure that subject had no MRI-
incompatible metallic object on or in his body. High resolution T1-weighted structural MRI 
images were acquired on a 3T Siemens Magnetom Verio Syngo MR B17 scanner (Siemens 
AG Healthcare, Germany) using 3D magnetisation-prepared rapid gradient-echo (MP-RAGE) 
sequence [330] (orientation = sagittal, repetition time (TR) = 2300ms, echo time (TE) = 
2.98ms, flip angle = 9o, voxel size = 1mm x 1mm x 1mm). 
 
 
Figure 30 Basic principle of PET imaging 
Adapted from http://www.scq.ubc.ca/looking-inside-the-human-body-using-positrons/ 
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3.1.6.2.1 PET imaging and analysis 
An intravenous cannula was inserted in the subject’s arm before the PET scanning 
session for administering the radio-tracer [11C]PBR28. The PET imaging was performed on 
Siemens Biograph™ TruePoint™ (Siemens Healthcare GmbH, Germany) PET/CT scanner 
(Figure 31). Prior to the PET scan, an x-ray topogram was performed to localise the brain. 
This was followed by a low dose CT scan localised to brain for attenuation and scatter 
corrections. Dynamic PET imaging was performed for 90 minutes after intravenous bolus 
administration of [11C]PBR28 over 20 seconds with a target dose of 400MBq. PET images 
were reconstructed using the filtered back projection (FBP) and ordered subset expectation 
maximisation (OSEM) algorithms and data archived. 
 
Figure 31 PET scanner at Imanova Centre for Imaging Sciences 
 
Data analyses were performed by Dr. Christopher Coello at Imanova Centre for 
Imaging Studies using MIAKATTM software (Imanova, London, UK). A modified version of the 
Harvard-Oxford cortical and sub-cortical structural atlas was non-linearly warped to the T1-
weighted structural image to outline cortical anatomy [331, 332]. Reconstructed dynamic PET 
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images were realigned for motion correction and registered to the T1-weighted structural MRI 
images. Regions of interest (ROI) were defined (frontal, temporal, parietal and occipital 
cortices) using the co-registered atlas. Based on the mean voxel radioactivity in each ROI and 
each frame, time activity curves (TAC) were derived for the full duration of the scan. Time-
averaged images of scan data were generated for a 30-min interval between 60-90 minutes. 
Whole brain, cerebellar and regional cortical standardised uptake values (SUV) were 
calculated after multiplying measured activity with the subject’s body weight and dividing by 
injected activity. Global and regional standardised uptake value ratios (SUVR) were calculated 
by dividing the SUV of whole brain and individual cortices by cerebellar SUV [333]. 
 
3.1.6.3 Statistical analysis 
 Demographic and neuropsychological testing data were analysed using SPSS version 
22.0 (SPSS Inc, Chicago, IL, USA). Mean + SEM was calculated for normally distributed 
quantitative variables. Independent sample t-test was applied to observe group mean 
differences. A p-value of <0.05 was considered statistically significant. 
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3.2 Bone study 
 
3.2.1 Bone volume fraction experiment 
3.2.1.1 Study design 
A cross-sectional analytical study design was employed to develop a measure for 
quantifying trabecular bone mass from femoral head CT scans with large voxels (up to 550μm) 
and determine whether the devised metric related to bone strength. 
 
3.2.1.2 Regulatory approvals 
Human femoral head samples used in this research project were obtained from the 
Imperial College Healthcare Tissue Bank (ICHTB). ICHTB is supported by the National 
Institute for Health Research (NIHR) Biomedical Research Centre (BRC) based at ICHT and 
Imperial College London. ICHTB is approved by the National Research Ethics Service (NRES) 
to release human material for research (12/WA/0196), and the samples for this project (Ref 
13004) were issued from sub-collection MEDA.  
 
3.2.1.3 Study sample 
Femoral heads (n=20) were collected post-operatively from patients giving informed 
consent undergoing hip arthroplasty for osteoarthritis or osteoporosis at Department of 
Orthopaedic Surgery, ICHT.  
 
3.2.1.4 Image acquisition 
Femoral heads were micro-CT scanned by Dr. Richard Abel at the Natural History 
Museum, London using a Nikon (Metris X-Tek) HMX-ST 225 CT system (Nikon Metrology, 
UK) (Figure 32) [334]. The CT scanner has a cone beam projection system with a four 
megapixel tungsten detector panel (Perkin Elmer XRD 1621 AN3 HS). Specimens were 
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mounted on a styrofoam base and placed onto a turntable inside the scanner. Specimens 
were scanned at fixed parameters of 180kV and 165A with a 0.1mm copper filter. A total of 
6315 projections were collected at an angular interval of 0.057O. The resulting scan for each 
femoral head had 2000 serial cross-sectional views with a cubic voxel size of 30µm. Scans 
were reconstructed using CT Pro 2.2 (Metris X-Tek, UK) and saved in the DICOM (Digital 
Imaging and Communications in Medicine) file format using VG Studio Max 2.0 (Volume 
Graphics, Heidelberg, Germany).  
 
 
Figure 32 CT scanner at Natural History Museum, London 
Adapted from http://www.nhm.ac.uk/research-curation/science-facilities/analytical-imaging/imaging/computed-
tomography/micro-ct/instrument/index.html 
 
3.2.1.5 Imaging data analysis 
Data were collected using external hard drives (NTFS format) and analyses were 
performed on a high power workstation (HP Z800) at the Musculoskeletal Lab, Imperial 
College London using the BoneJ (version 1.3.1) plugin for bone image analysis in ImageJ 
(version 1.48d)  software (Java image processing program) [335]. The micro-CT DICOM data 
files were imported into ImageJ and serially downgraded in resolution from 30µm to 50, 100, 
200, 400 and 550µm voxel size (Figure 33). 
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Figure 33 Downgradation of micro-CT data from high to low resolution 
a. A slice of high resolution (30µm) micro-CT scan and 3D model of femoral head built from 
micro-CT scan b. A slice of low resolution (550µm) scan downgraded from 30µm 3D model 
of femoral head built from downgraded scan 
  
Spheres of trabecular bone were virtually sectioned from all the high and low-resolution 
3D scans of the femoral heads. This was done to ensure that only trabecular bone was 
analysed and cortical region was excluded. The largest sphere possible was collected about 
the centre of the femoral head. To do so, orthogonal views of the images were opened. The 
biggest slice of femoral head on the Z-axis view was located (Figure 34) and then 
corresponding slices on the X- and Y-axes were identified. Largest fitting circles that excluded 
cortical bone from the femoral head were then drawn on to the slices identified on the X- and 
Y-axes (Figure 34). ROI markers were placed one each on the bottom, top and lateral ends of 
the circles and entered into the ROI manager. As defined by the 8 ROI markers, a sphere was 
sectioned for each scan using the sphere fitting algorithm in BoneJ (Figure 4). 
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Figure 34 Orthogonal views used for sectioning a sphere 
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Bone J plugin required binary images for trabecular analyses. For this purpose, 
frequency distribution plots of the voxel grey values were plotted using the ‘histogram’ function 
in ImageJ. Threshold grey values were calculated by finding the trough that separated bone 
and non-bone peaks [336, 337]. Based on the threshold values, black and white binary images 
were generated using the ‘threshold’ function in ImageJ (Figure 35). Trabecular BVF was 
measured by counting voxels representing bone using the BVF function in BoneJ. Data were 
entered into Excel spreadsheet (Microsoft Excel 2013). The accuracy of lower-resolution 
metrics was validated against the high-resolution data by plotting scatter graphs and 
calculating correlation coefficients (R2).  
 
 
Figure 35 Binary image of a slice of sphere from a femoral head micro-CT scan 
Trabecular microstructure clearly visible at high resolution 
 
3.2.1.6 Bone strength testing 
Mechanical testing of the femoral heads was employed to assess bone strength. Eight 
(out of the 20) femoral heads from patients who underwent hip replacement for osteoarthritis 
were mechanically tested. Testing was performed by Dr. Andi Jin at the Department of 
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Mechanical Engineering, Imperial College London. Femoral heads were sectioned and five 
cylindrical sub-samples (10mm in height and 7mm in diameter) were drilled out from the 
central trabecular part of each femoral head (Figure 36).  
 
Figure 36 Sectioning and drilling of femoral heads in preparation for mechanical testing 
a. Whole femoral head b.) Five cylindrical sub-samples (7mm diameter, 10mm height) drilled 
out from the femoral head 
 
Two sub-samples from the five were selected randomly and mechanically tested until 
fracture under uniaxial compressive loading (Figure 37) using an Instron 5565 mechanical test 
machine (Instron Engineering Corporation, USA). The maximum load (the peak of the graph 
shown in Figure 37, which corresponded with fracture) divided by specimen cross-sectional 
area, was used to calculate the bone strength of each cylindrical specimen [338]. Mean 
strength of the two specimens for each femoral head was computed and the relationships 
between BVF values and measures of ex-vivo bone strength were determined by plotting 
scatter graphs and calculating R2. 
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Figure 37 Mechanical testing to assess bone strength of femoral head samples 
a. Cylindrical sub-samples of femoral heads were uniaxially compressed to fracture b. 
Mechanical behaviour of the tested specimen as seen on load-displacement graph. Peak of 
the graph represents the maximum load sustained 
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3.2.2 Bone alkaline phosphatase experiment 
3.2.2.1 Study design 
A longitudinal study design was employed for this study to determine changes in serum 
BALP in patients with non-metastatic PC following initiation of ADT with LHRHa and to relate 
those changes to serum testosterone and oestradiol levels.  
 
3.2.2.2 Regulatory approvals 
Blood samples were collected as ICHTB sub-collection Sur_PA_12_044 and were 
later issued for BALP analysis following ICHTB approval (Ref R14110) (Appendix II). 
 
3.2.2.3 Study population 
Patients with PC (n=9) between the ages 50 to 75 years who were to begin ADT with 
LHRHa for either newly diagnosed advanced non-metastatic disease or as adjuvant or 
neoadjuvant to RT for localised disease provided blood samples for the study. Written 
informed consent was obtained and blood samples were taken at baseline before starting 
treatment and three months afterward. Comparisons were made with blood samples taken at 
similar time points from age-matched controls without PC (n=9). Blood samples were 
centrifuged at 3000 rpm for 10 minutes and separated serum was stored at -80oC until 
assayed. 
 
3.2.2.4 Serum BALP and sex hormone assays  
 Serum BALP assays were performed by Dr. Alan Courtney at the Imperial Bone Marker 
Service, Charing Cross Hospital. Serum BALP was measured using the Metra® BALP enzyme 
immunoassay (EIA) kit (Quidel® Corporation, San Diego, California, USA) [339]. The assay 
utilised monoclonal anti-BALP antibodies which were coated on a micrititer strip to capture 
BALP in the serum samples. The enzyme activity of the captured BALP was detected with 
para-nitrophenylphosphate (pNPP) which is a chromogenic substrate of BALP. The enzyme 
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BALP catalysed the hydrolysis of pNPP to yellow coloured para-nitrophenol which was 
measured using a visible light spectrophotometer at a wavelength of 405 nm to provide a 
quantitative measure of serum BALP activity [339]. 
Serum samples were analysed at Imperial Clinical Chemistry Laboratory, Charing 
Cross Hospital for quantitative determination of testosterone and oestradiol using 
commercially available kits. Serum testosterone was measured by the single-step 
ARCHITECT® testosterone 56-4969/R1 B7K730 assay (Abbott Laboratories, Abbott Park, 
Illinois, USA) using Chemiluminescent Microparticle Immunoassay (CMIA) technology with 
Chemiflex™ protocol (Abbott Laboratories, Abbott Park, Illinois, USA). Serum sample, 
paramagnetic microparticles coated with murine monoclonal anti-testosterone antibody, 
acridinium-labeled testosterone conjugate and assay diluent were combined to create the 
reaction mixture. Testosterone present in the sample competed with the acridinium-labeled 
testosterone conjugate for binding with anti-testosterone coated microparticles to form an 
antigen-antibody complex. After washing, pre-trigger and trigger solutions were then added to 
the reaction mixture and the resulting chemiluminescent reaction was measured as relative 
light units (RLU) detected by the ARCHITECT® i optical system (Abbott Laboratories, Abbott 
Park, Illinois, USA). The amount of total testosterone in the assayed serum sample was 
determined from a calibration curve established with RLU calibrators of known testosterone 
concentrations. The lowest detection limit of the testosterone assay was 0.45 nmol/L [340]. 
Serum oestradiol was measured using the two-step ARCHITECT® oestradiol 48-
9132/R3 B7K720 assay (Abbott Laboratories, Abbott Park, Illinois, USA) using CMIA 
technology with Chemiflex™ protocol (Abbott Laboratories, Abbott Park, Illinois, USA). In the 
first step, sample, specimen diluent, assay diluent, and paramagnetic microparticles coated 
with anti-oestradiol antibody (rabbit, monoclonal) were combined to prepare reaction mixture. 
Oestradiol present in the sample bound to the anti-oestradiol coated microparticles. In the 
second step, acridinium-labeled oestradiol conjugate was added to the reaction mixture. After 
washing, pre-trigger and trigger solutions were added and the chemiluminescence generated 
was measured as relative light units (RLU) detected by the ARCHITECT® i optical system 
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(Abbott Laboratories, Abbott Park, Illinois, USA). The concentration of total oestradiol in the 
assayed serum sample was determined from a calibration curve established with RLU 
calibrators of known oestradiol concentrations. The lowest detection limit of the oestradiol 
assay was 37 pmol/L [341]. 
 
3.2.2.5 Statistical analysis 
The data were entered and analysed using SPSS version 22.0 (SPSS Inc, Chicago, 
Illinois, USA). Age data were presented as range and mean. Mean + S.E.M was calculated 
for normally distributed quantitative variables. One-way ANOVA was applied to observe group 
mean differences and post-hoc Tukey test was applied to observe which group means differ. 
Pearson’s correlation was applied to observe correlation between BALP and serum sex 
hormone levels. A p-value of <0.05 was considered statistically significant.  
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3.3 Odour study 
3.3.1 Study design 
A longitudinal study design was employed for this study to determine changes in social 
perception of odour samples of patients with PC receiving ADT with LHRHa. Study subjects 
provided samples at baseline before starting treatment and three months after initiation of ADT 
with LHRHa. Comparisons were made with age-matched controls. 
 
3.3.2 Regulatory approvals 
Human samples used in this study were collected as ICHTB sub-collection 
Sur_PA_12_044. Collected samples were stored in a -80oC freezer at the Medical Oncology 
and Biochemistry Laboratory, Charing Cross Hospital, ICHT. Stored samples were later 
issued for analysis following ICHTB approval (Ref R14110) (Appendix II). ICHTB is funded 
under the tissue banking theme of NIHR Imperial BRC, and approved by the NRES to release 
human material for research (12/WA/0196). 
 
3.3.3 Study population 
Study samples were provided by two population groups; (i) patients with PC 
undergoing ADT with LHRHa (n=10) and (ii) age-matched male patients without PC as 
controls (n=10). Patients who were to commence ADT with LHRHa for PC treatment were 
approached at the uro-oncology clinics of ICHT to provide odour and blood samples for this 
study. Age matched male patients without PC who presented to the urology clinics with other 
urological complaints were approached to enrol as controls. Written informed consent was 
obtained from each participant as outlined by the ICHTB. The purpose of the study was 
introduced in full and then consent taken. All study documents were kept at a secure ICHT 
location. 
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3.3.4 Eligibility criteria 
Male patients between the ages 50 to 75 years who were to begin ADT with LHRHa 
for either newly diagnosed advanced PC or as adjuvant or neoadjuvant to RT for localised 
disease were invited to co-operate with the study. 
 
3.3.5 Odour sample collection 
Axillary odour samples were collected on white T-shirts worn by the study participants. 
Experimental materials, including a white cotton T-shirt, a non-perfumed soap bar and a zip-
lock plastic bag, were provided to the participants. The participants were required to wear 
each T-shirt overnight for two consecutive nights [71]. They were instructed to follow a strict 
hygiene regime commencing 24 hours before sampling. The instructions included abstinence 
from sexual activity, not sharing a bed, avoiding deodorants and other perfumed products, 
using the provided non-perfumed soap (Simple pure soap bar, UK), wearing only the provided 
cotton T-shirts (prewashed in non-perfumed detergent) while sleeping at night, avoidance of 
tobacco smoke, alcohol and strong smelling foods (e.g. chilli, garlic, pepperoni, curry, blue 
cheese, asparagus, yogurt and fried onion) [342]. Subjects were requested to shower just 
before going to bed on each of the two consecutive nights, wear the T-shirts in bed and to 
return them to the provided bags each morning. The T-shirts were collected on the second 
morning in their sealed plastic bags. The bottom half of each T-shirt, below the rib cage, was 
cut and discarded. The remaining part of each T-shirt was put in its zip-lock plastic bag which 
was labelled in an anonymised form with key codes indicating only the group (PC or control) 
and treatment stage (baseline or three month sample). The plastic bag containing the sample 
was frozen and stored at -80oC on the same day until studied. Freezing avoids changes in 
subsequent odour perception [343]. Gloves were worn during the handling of T-shirts to avoid 
odour contamination. 
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3.3.6 Odour bioassays 
 Odour bioassays were performed at Dr. S Craig Robert’s laboratory, Department of 
Psychology, University of Stirling, Scotland. The stored samples were transported overnight 
and were kept frozen in an insulated box containing dry ice during transport. The samples 
were immediately put into a freezer upon arrival at the site. 
The zip-lock plastic bags containing the T-shirts were removed from the freezer 2 hours 
before the testing. The samples were left to thaw at room temperature. The bags were shaken 
thoroughly and inverted several times just before the smelling sessions. A group of 100 young 
healthy adult heterosexual university students (50 females, 50 males) were recruited to sniff 
and rate individual odour samples. Only those females who were using hormonal 
contraception were recruited to rate the odour samples. Hormonal contraceptive users were 
employed to avoid the potential effect of fluctuations in olfactory function during the natural 
menstrual cycle. Before recruitment, information about the study was given to the participants 
and written consent obtained. Participants were asked to rate individual samples for their 
masculinity, attractiveness and intensity, using a 7-point scale (from 1-very low to 7-very high) 
(Appendix III). They were also asked to complete a questionnaire containing some basic 
demographic items (e.g. age, sex). Participants then smelled and rated a series of 8 individual 
odours each (baseline and 3 month samples from 2 controls and 2 PC patients each). The 
raters were blinded to the identity of the samples and their responses were kept anonymous. 
Shirts were discarded on completion of the rating experiment. 
 
3.3.7 Sex hormones assays 
Venous blood samples for measurement of testosterone and oestradiol levels were 
obtained from the subjects in the study group on two occasions: (i) immediately before starting 
ADT with LHRHa and (ii) three months after initiation of ADT. Subjects in the control group 
also provided blood samples twice according to the same time schedule as described for 
subjects in the study group. Blood samples were spun down at 3000 rpm for 10 minutes to 
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separate serum from the cells and aliquoted serum specimens were stored at -80oC until 
assayed.  
Quantitative determination of serum testosterone and oestradiol was carried out at 
Imperial Clinical Chemistry Laboratory, Charing Cross Hospital using commercially available 
kits (detailed description given in section 3.2.2.4). Serum testosterone was measured by the 
single-step ARCHITECT® testosterone 56-4969/R1 B7K730 assay (Abbott Laboratories, 
Abbott Park, Illinois, USA) using CMIA technology with Chemiflex™ protocol (Abbott 
Laboratories, Abbott Park, Illinois, USA) [340]. Serum oestradiol was measured using the two-
step ARCHITECT® oestradiol 48-9132/R3 B7K720 assay (Abbott Laboratories, Abbott Park, 
Illinois, USA) using CMIA technology with Chemiflex™ protocol (Abbott Laboratories, Abbott 
Park, Illinois, USA) [341]. 
 
3.3.8 Statistical Analysis 
Data were statistically analysed in an anonymised form. Odour ratings data were 
entered into Excel spreadsheet (Microsoft Excel 2013). Averages were computed for 
attractiveness, masculinity and intensity ratings by male raters, female raters and all raters 
combined. The rating averages were then imported into and analysed using SPSS version 
22.0 (SPSS Inc, Chicago, Illinois, USA). Serum sex hormones and demographic data were 
also entered into and analysed using SPSS version 22.0 (SPSS Inc, Chicago, Illinois, USA). 
Age data were presented as range and mean. Qualitative data were presented as 
percentages. Mean + S.E.M was calculated for normally distributed quantitative variables. 
One-way ANOVA was applied to observe group mean differences and post-hoc Tukey test 
was applied to observe which group means differ. Pearson’s correlation was applied to 
observe correlation between odour ratings and serum sex hormone levels. A p-value of <0.05 
was considered statistically significant. 
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4. Results 
4.1 Cognitive study 
A total of 10 patients who consented for the study underwent stage 1 procedures 
(TSPO polymorphism test and neuropsychological testing). Figure 38 summarises 
recruitment for the study and Table 8 describes characteristics of the study participants. 
 
 
Figure 38 Recruitment summary for cognitive study 
  
126 
 
Table 8 Descriptive characteristics of study participants (n=10) 
Age  Mean = 68 years 
Range= 57-77 years 
ADT duration Mean = 7 months 
Range = 4-11 months 
Stage 1 groups Cognitive impairment (n=4) 
Control (n=6) 
TSPO Polymorphism High binding affinity (n=4) 
Medium binding affinity (n=2) 
Low binding affinity (n=4) 
PET Imaging Cognitive impairment (n=2) 
Control (n=2) 
 
The age range of ‘cognitive impairment’ (CI) group was 59-77 years with a mean age 
of 71.7 years. The age range of control group was 57-71 years with a mean age of 64.8 
years. The range of ADT duration in CI group was 4-11 months with a mean duration of 7.2 
months. The range of ADT duration in control group was 4-11 months with a mean duration 
of 7.3 months. The range of MMSE score in CI group was 24-29 with a mean of 26.2. The 
range of MMSE score in control group was 24-30 with a mean of 27.8. The range of WTAR 
score in CI group was 90-114 with a mean of 105. The range of WTAR score in control 
group was 97-123 with a mean of 114.There was no significant difference between the two 
groups in terms of age, ADT duration, MMSE score and WTAR score (Table 9). 
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Table 9 Group comparison of age, duration of ADT, MMSE and WTAR scores 
 CI (n=4) 
Mean + SEM 
Control (n=6) 
Mean + SEM 
p-value 
Age (years) 71.75 + 4.3 64.83 + 2.24 0.156 
ADT duration (months)  7.25 + 1.43 7.33 + 1.14 0.960 
MMSE score 26.25 + 1.31 27.83 + 0.87 0.324 
WTAR score 105.00 + 5.44 114.00 + 3.86 0.202 
 
A general trend of poor performance on all the paper-based neuropsychological tests 
was observed in the CI group as compared to controls (Table 10). Significant differences were 
observed between test scores of CI group and control group on ‘People Test Immediate 
Recall’ (13.00+0.70 vs. 21.33+1.52; p=0.003), ‘People Test Delayed Recall’ (1.50+0.64 vs. 
6.83+0.47; p=0.000), ‘CWIT Word Reading’ (26.75+1.49 vs. 22.83+0.70; p=0.029), ‘CWIT 
Inhibition’ (114.00+24.75 vs. 67.83+2.56; p=0.048) and ‘Letter Fluency’ (31.00+3.34 vs. 
48.83+2.41; p=0.002) (Table 10). No significant differences were observed between the two 
groups on any of the computer-based tests (Table 11).   
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Table 10 Group comparison of paper-based test scores 
 CI (n=4) 
Mean + SEM 
Control (n=6) 
Mean + SEM 
p-value 
Trail Making A* 46.25 + 10.07 39.17 + 3.30 0.453 
Trail Making B* 121.75 + 13.36 106.67 + 6.55 0.292 
People Test  
Immediate Recall 
13.00 + 0.70 21.33 + 1.52 0.003** 
People Test 
Delayed Recall 
1.50 + 0.64 6.83 + 0.47 0.000** 
CWIT Colour Naming* 47.75 + 6.96 35.33 + 2.45 0.085 
CWIT Word Reading* 26.75 + 1.49 22.83 + 0.70 0.029** 
CWIT Inhibition* 114.00 + 24.75 67.83 + 2.56 0.048** 
CWIT Inhibition Switching* 110.00 + 26.19 75.33 + 3.66 0.141 
Letter Fluency 31.00 + 3.34 48.83 + 2.41 0.002** 
Logical Memory  
Immediate Recall 
31.50 + 3.42 34.00 + 2.51 0.564 
Logical Memory 
Delayed Recall 
13.00 + 2.27 17.50 + 1.38 0.109 
Logical Memory 
Recognition 
22.25 + 1.88 23.50 +0.61 0.478 
Similarities 27.00 + 8.40 35.67 + 5.53 0.082 
Matrix Reasoning 13.00 + 6.37 19.33 + 5.61 0.135 
Digit Span 12.75 + 2.98 15.67 + 2.65 0.143 
*Higher score implies lower performance on test 
** Difference significant at p<0.05 
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Table 11 Group comparison of computer-based test scores 
 CI (n=4) 
Mean + SEM 
Control (n=6) 
Mean + SEM 
p-value 
Digit Span 5.50 + 0.28 5.50 + 0.42 1.000 
Spatial Span 3.75 + 0.75 3.83 + 0.47 0.924 
Paired Associates 3.00 + 0.40 3.16 + 0.30 0.748 
Self-Ordered Search 6.00 + 0.91 6.00 + 0.25 1.000 
Spatial Rotation 49.75 + 7.60 38.00 + 7.00 0.301 
Feature Match 60.75 + 7.01 69.16 + 13.38 0.646 
Polygons 19.50 + 7.13 18.50 + 5.44 0.913 
Monkey Span 5.50 + 0.64 6.33 + 0.42 0.289 
Double Trouble 7.75 + 2.13 9.00 + 2.30 0.718 
Verbal Reasoning 8.50 + 2.32 7.16 + 1.70 0.648 
Odd One Out 12.25 + 0.62 12.00 + 0.81 0.831 
Hampshire Tree Task 5.25 + 0.75 7.66 + 1.80 0.330 
*Difference significant at p<0.05 
 
4 of the 10 patients who underwent stage 1 procedures were found to have a high 
affinity binding TSPO polymorphism (n=2 each in the control and CI groups). These patients 
continued to stage 2 and underwent TSPO PET imaging. TACs for the full duration of scan (0-
90 minutes) were plotted for global and regional brain SUVs and SUVRs (Figures 39,40). 
Time-averaged images of PET scan SUVR data generated for a 30-min interval between 60-
90 minutes showed a diffuse TSPO uptake pattern in the brain (Figure 41). The CI subjects 
showed higher time-averaged whole brain SUVR (mean SUVR between scan times of 60-90 
minutes) as compared to controls (CI 0.985 vs. Controls 0.92). The frontal, parietal, temporal 
and occipital SUVRs were also higher in the CI subjects as compared to control subjects 
(Table 12). 
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Figure 39 Time activity curves of SUV in the PET scanned study subjects 
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Figure 40 Time activity curves of SUVR in the PET scanned study subjects
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Figure 41 Time averaged PET images showing brain TSPO uptake pattern 
 
Table 12 Time averaged global and regional brain SUVR (60-90 minutes) 
 
Control (n=2) CI (n=2) 
Brain 0.92 0.985 
Frontal Lobe 0.91 1.005 
Temporal Lobe 0.905 0.97 
Parietal lobe 0.865 0.995 
Occipital lobe 0.93 1.03 
Cerebellum 1 1 
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4.2 Bone study 
4.2.1 Bone volume fraction experiment 
BVF data collected at high resolution (30µm voxel size) were highly correlated (R2 > 
0.9) with BVF data collected at serially downgraded lower resolutions (50, 100, 200, 400 and 
550µm voxel sizes) (Figures 42-46). A high correlation (R2 = 0.9032) was seen between BVF 
measures calculated from high resolution (30µm voxel size) micro-CT images and BVF values 
measured at the lowest downgraded resolution (550µm voxel size) (Figure 46). 
 
 
Figure 42 Scatter diagram of BVF measures at 30µm and 50µm resolutions 
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Figure 43 Scatter diagram of BVF measures at 30µm and 100µm resolutions 
 
 
 
Figure 44 Scatter diagram of BVF measures at 30m and 200m resolutions 
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Figure 45 Scatter diagram of BVF measures at 30µm and 400µm resolutions 
 
 
 
Figure 46 Scatter diagram of BVF measures at 30µm and 550m resolutions 
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The BVF metrics calculated from high resolution (30µm voxel size) micro-CT images 
were highly correlated (R2=0.953) with the mean of the bone strengths calculated ex vivo for 
the two cylindrical specimens from each femoral head (Figure 47). A similar high positive 
correlation (R2=0.959) was observed between BVF measures at the lowest downgraded 
resolution (550µm voxel size) and ex-vivo bone strength (Figure 48). 
 
 
Figure 47 Scatter diagram of BVF values calculated from high resolution (30mµ) micro-CT 
images and ex-vivo bone strength measures 
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Figure 48 Scatter diagram of BVF values calculated from lowest downgraded resolution 
(550µm) images and ex-vivo bone strength measures 
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4.2.2 Bone alkaline phosphatase experiment 
The age range of control group was 50-73 years with a mean age of 62.11 years. The 
age range of study group was 59-75 years with a mean age of 70.22 years. 
 
Table 13 Group characteristics of BALP, testosterone and oestradiol 
Parameter 
 
Control group n=9 
Mean + S.E.M 
Study group n=9 
Mean + S.E.M 
p-value 
 
Baseline 3 months Baseline 3 months 
BALP (U/L) 32.01 + 4.69 36.14 + 4.94 26.15 + 2.22 26.17 + 3.62 0.242 
Testosterone 
(nmol/l) 
15.72 + 1.89 14.85 + 2.05 17.04 + 1.47 0.66 + 0.14 0.000* 
Oestradiol 
(pmol/l) 
102.78 + 
13.41 
93.78 + 7.45 90.56 + 9.35 37.00 + 0.00 0.000* 
*Difference is significant at p<0.05 
 
The BALP range of control group at baseline was 20.4-65 U/L with a mean of 32.01 
U/L. The BALP range of control group at 3 months was 24.0-65.2 U/L with a mean of 36.14 
U/L. The BALP range of study group at baseline was 16.7-34.4 U/L with a mean of 26.15 U/L. 
The BALP range of study group at 3 months after start of ADT was 15.7-45.6 U/L with a mean 
of 26.17 U/L (Figure 49). No significant difference in BALP levels was observed between 
groups (p=0.242) (Table 13). The testosterone range of control group at baseline was 9.19-
27.70 nmol/L with a mean of 15.72 nmol/L. The testosterone range of control group at 3 
months was 9.41-22.55 nmol/L with a mean of 14.85 nmol/L. The testosterone range of study 
group at baseline was 9.31-21.40 nmol/L with a mean of 17.04 nmol/L. The testosterone range 
of study group 3 months after start of ADT was 0.45-1.42 nmol/L with a mean of 0.66 nmol/L 
(Figure 49). Significant difference in testosterone levels was observed between groups 
(p=0.000) (Table 13). The oestradiol range of control group at baseline was 46-175 pmol/L 
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with a mean of 102.78 pmol/L. The oestradiol range of control group at 3 months was 56-131 
pmol/L with a mean of 93.78 pmol/L. The oestradiol range of study group at baseline was 51-
147 pmol/L with a mean of 90.56 pmol/L. The mean value of oestradiol in the study group at 
3 months after start of ADT was 37 pmol/L (Figure 49). Significant difference in oestradiol 
levels was observed between groups (p=0.000) (Table 13). 
 
 
Figure 49 Mean BALP, testosterone and oestradiol levels in control and study groups at 3 
months assessment 
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After applying post-hoc Tukey test, testosterone levels were significantly lower in the 
study group at 3 months than the study group at baseline as well as the control group at both 
assessments (baseline and 3 months) (p=0.001) (Table 14) (Figure 49). Oestradiol levels of 
study group at 3 months assessment were significantly lower than oestradiol levels of study 
group at baseline assessment and control group at both time points (baseline and 3 months) 
(p<0.001) (Table 15) (Figure 49). 
No significant correlation was observed between serum testosterone and serum BALP 
levels (R=0.187, p=0.276) (Figure 50). No significant correlation was observed between serum 
oestradiol and BALP levels (R=0.055, p=0.75) (Figure 51).  
 
Table 144 Group comparisons of testosterone at baseline and 3 months 
Group 1 Group 2 p-value 
Control 
(Baseline) 
Control (3 months) 0.980 
Study (Baseline) 0.934 
Study (3 months) 0.000* 
Control 
(3 months) 
Control (Baseline) 0.980 
Study (Baseline) 0.762 
Study (3 months) 0.000* 
Study  
(Baseline) 
Control (Baseline) 0.934 
Control (3 months) 0.762 
Study (3 months) 0.000* 
Study 
(3 months) 
Control (Baseline) 0.000* 
Control (3 months) 0.000* 
Study (Baseline) 0.000* 
*Difference is significant at p<0.05. 
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Table 155 Group comparisons of oestradiol at baseline and 3 months 
Group Group p-value 
Control 
(Baseline) 
Control (3 months) 0.893 
Study (Baseline) 0.772 
Study (3 months) 0.001* 
Control 
(3 months) 
Control (Baseline) 0.893 
Study (Baseline) 0.994 
Study (3 months) 0.001* 
Study  
(Baseline) 
Control (Baseline) 0.772 
Control (3 months) 0.994 
Study (3 months) 0.001* 
Study 
(3 months) 
Control (Baseline) 0.000* 
Control (3 months) 0.001* 
Study (Baseline) 0.001* 
*Difference is significant at p<0.05. 
 
 
Figure 50 Scatter diagram of serum testosterone and BALP levels 
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Figure 51 Scatter diagram of serum oestradiol and BALP levels 
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4.3 Odour study 
The age range of study group (n=10) was 50-74 years with a mean age of 63.3 years. 
The age range of control group (n=10) was 59-75 years with a mean age of 69.6 years. Figure 
52 describes the ethnic distribution of the study participants who provided odour samples. 
 
 
Figure 52 Ethnic distribution of study population 
 
The age range of male raters (n=50) was 17-33 years with a mean age of 21.56 years. 
The age range of female raters (n=50) was 17-34 years with a mean age of 21.26 years. The 
age range of all raters (male and female, n=100) was 17-34 years with a mean age of 21.41 
years. 
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Table 16 Group characteristics of odour ratings for attractiveness, masculinity and intensity 
by male raters 
Parameter 
 
Control group n=10 
Mean + S.E.M 
Study group n=10 
Mean + S.E.M 
p-value 
 
Baseline 3 months Baseline 3 months 
Attractiveness 2.92 + 0.16 2.92 + 0.13 2.72 + 0.18 2.82 + 0.14 0.778 
Masculinity 3.13 + 0.15 2.78 + 0.14 3.27 + 0.10 3.21 + 0.13 0.079 
Intensity 3.26 + 0.33 2.61 + 0.17 3.16 + 0.22 3.02 + 0.18 0.241 
 
 
Table 177 Group characteristics of odour ratings for attractiveness, masculinity and intensity 
by female raters 
Parameter 
 
Control group n=10 
Mean + S.E.M 
Study group n=10 
Mean + S.E.M 
p-value 
 
Baseline 3 months Baseline 3 months 
Attractiveness 2.68 + 0.22 2.72 + 0.24 2.55 + 0.11 2.61 + 0.20 0.933 
Masculinity 2.94 + 0.13 2.82 + 0.22 2.85 + 0.17 2.74 + 0.20 0.900 
Intensity 3.03 + 0.30 2.73 + 0.18 2.87 + 0.24 2.63 + 0.18 0.650 
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Table 188 Group characteristics of odour ratings for attractiveness, masculinity and intensity 
by all raters (males and females) 
Parameter 
 
Control group n=10 
Mean + S.E.M 
Study group n=10 
Mean + S.E.M 
p-value 
 
Baseline 3 months Baseline 3 months 
Attractiveness 2.81 + 0.17 2.83 + 0.15 2.64 + 0.12 2.72 + 0.13 0.803 
Masculinity 3.03 + 0.09 2.80 + 0.12 3.06 + 0.07 2.98 + 0.11 0.329 
Intensity 3.14 + 0.29 2.67 + 0.14 3.02 + 0.16 2.82 + 0.15 0.374 
 
One-way ANOVA test did not show any difference in the ratings for attractiveness, 
masculinity or intensity by male raters, female raters or both male and female raters combined 
(Tables 16,17,18). 
 
Table 19 Group characteristics of serum sex hormone levels 
Parameter 
 
Control group n=10 
Mean + S.E.M 
Study group n=10 
Mean + S.E.M 
p-value 
 
Baseline 3 months Baseline 3 months 
Testosterone 
nmol/L 
16.55 + 1.88 16.58 + 
1.45 
16.56 + 1.45 0.64 + 0.12 0.000* 
Oestradiol 
pmol/L 
102.70 + 
12.00 
95.10 + 
6.79 
89.40 + 8.44 37.00 + 0.00 0.000* 
*Difference is significant at p<0.05. 
 
The testosterone range of control group at baseline was 9.19-27.70 nmol/L with a 
mean of 16.55 nmol/L. The testosterone range of control group at 3 months was 9.41-22.55 
nmol/L with a mean of 16.58 nmol/L. The testosterone range of study group at baseline was 
9.31-21.40 nmol/L with a mean of 16.56 nmol/L. The testosterone range of study group 3 
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months after start of ADT was 0.45-1.42 nmol/L with a mean of 0.64 nmol/L (Figure 53). 
Significant difference in testosterone levels was observed between groups (p=0.000) (Table 
19). The oestradiol range of control group at baseline was 46-175 pmol/L with a mean of 
102.70 pmol/L. The oestradiol range of control group at 3 months was 56-131 pmol/L with a 
mean of 95.10 pmol/L. The oestradiol range of study group at baseline was 51-147 pmol/L 
with a mean of 89.40 pmol/L. The mean value of oestradiol in the study group at 3 months 
after start of ADT was 37 pmol/L (Figure 53). Significant difference in oestradiol levels was 
observed between groups (p=0.000) (Table 19). 
 
 
Figure 53 Mean serum testosterone and oestradiol levels in control and study groups at 3 
months assessment 
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Table 190 Group comparisons of serum testosterone levels 
Group 1 Group 2 p-value 
Control 
(Baseline) 
Control (3 months) 1.000 
Study (Baseline) 1.000 
Study (3 months) 0.000* 
Control 
(3 months) 
Control (Baseline) 1.000 
Study (Baseline) 1.000 
Study (3 months) 0.000* 
Study  
(Baseline) 
Control (Baseline) 1.000 
Control (3 months) 1.000 
Study (3 months) 0.000* 
Study 
(3 months) 
Control (Baseline) 0.000* 
Control (3 months) 0.000* 
Study (Baseline) 0.000* 
*Difference is significant at p<0.05 
 
 
Table 201 Group comparisons of serum oestradiol levels 
Group 1 Group 2 p-value 
Control 
(Baseline) 
Control (3 months) 0.910 
Study (Baseline) 0.654 
Study (3 months) 0.000* 
Control 
(3 months) 
Control (Baseline) 0.910 
Study (Baseline) 0.959 
Study (3 months) 0.000* 
Study  
(Baseline) 
Control (Baseline) 0.654 
Control (3 months) 0.959 
Study (3 months) 0.000* 
Study 
(3 months) 
Control (Baseline) 0.000* 
Control (3 months) 0.000* 
Study (Baseline) 0.000* 
*Difference is significant at p<0.05 
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After applying post-hoc Tukey test, testosterone levels were significantly lower in the 
study group at 3 months than the study group at baseline as well as the control group at both 
assessments (baseline and 3 months) (p=0.001) (Table 20) (Figure 53). Oestradiol levels of 
study group at 3 months assessment were significantly lower than oestradiol levels of study 
group at baseline assessment and control group at both time points (baseline and 3 months) 
(p=0.000) (Table 21) (Figure 53). 
No significant correlation was observed between serum sex hormone levels and odour 
ratings by male or female raters and by all raters combined (Table 22-24) (Figures 54-59).  
 
Variable 1 Variable 2 Pearson’s R p-value 
Testosterone Attractiveness 0.059 0.716 
Masculinity -0.131 0.422 
Intensity -0.01 0.995 
Oestradiol Attractiveness 0.015 0.926 
Masculinity -0.296 0.064 
Intensity -0.206 0.202 
Table 21 Correlation between sex hormone levels and odour ratings by male raters 
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Variable 1 Variable 2 Pearson’s R p-value 
Testosterone Attractiveness -0.042 0.799 
Masculinity 0.057 0.728 
Intensity 0.196 0.226 
Oestradiol Attractiveness 0.136 0.404 
Masculinity 0.008 0.962 
Intensity 0.038 0.818 
Table 22 Correlation between sex hormone levels and odour ratings by female raters 
 
 
Variable 1 Variable 2 Pearson’s R p-value 
Testosterone Attractiveness 0.010 0.952 
Masculinity -0.046 0.777 
Intensity 0.114 0.483 
Oestradiol Attractiveness 0.103 0.528 
Masculinity -0.190 0.239 
Intensity -0.096 0.555 
Table 23 Correlation between sex hormone levels and odour ratings by all raters 
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Figure 54 Scatter diagram of serum testosterone and odour ratings by male raters 
 
 
Figure 55 Scatter diagram of serum oestradiol and odour ratings by male raters 
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Figure 56 Scatter diagram of serum testosterone and odour ratings by female raters 
 
 
Figure 57 Scatter diagram of serum oestradiol and odour ratings by female raters 
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Figure 58 Scatter diagram of serum testosterone and odour ratings by all raters 
 
 
Figure 59 Scatter diagram of serum oestradiol and odour ratings by all raters 
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5. Discussion 
5.1 Cognitive study 
 This current study explored for the first time the presence of neural pathological 
changes related to cognitive impairment in patients with PC undergoing ADT with LHRHa. The 
study employed PET brain imaging using radioligand [11C]PBR28 for the neuroinflammatory 
marker TSPO known to be overexpressed by the neuroimmune microglial cells activated by 
brain disease or damage [283, 284]. An increased global and regional uptake of the 
radioligand was seen in whole brain and frontal, parietal, temporal and occipital cortices of 
patients complaining of or noticing cognitive deterioration since starting on LHRHa treatment 
(Figure 41) (Table 12).  
This work has yielded findings consistent with neuroinflammatory response in the 
setting of cognitive decline in PC patients receiving ADT. Studies on clinical conditions 
including stroke, multiple sclerosis, mild cognitive impairment (MCI) and AD have previously 
utilised TSPO PET imaging to visualise neuroinflammatory changes [284, 285, 344, 345]. The 
present study utilised mean SUVR between the scanning period of 60-90 minutes as the tissue 
uptake parameter of [11C]PBR28 to compare the groups (men reporting cognitive decline 
since starting LHRHa and men not reporting such change) as shown recently by Lyoo et al 
[333]. Their study of patients suffering from AD demonstrated no difference in cerebellar 
binding of [11C]PBR28 between healthy controls (n=21) and patients with MCI (n=11) or AD 
(n=25), thus justifying its use as a pseudo-reference region for clinical TSPO PET imaging to 
calculate SUVR. They further showed significantly higher [11C]PBR28 SUVR in patients with 
AD as compared to healthy controls in the regional cortices (temporal, parietal) (p < 0.009) 
[333].  
The imaging component of the current study has a sample size smaller than other 
TSPO PET imaging studies which did not allow the use of statistical methods for assessing 
significance of the differences observed. However, the study had the advantage of including 
only those patients who were shown to have HAB TSPO polymorphism. It has been shown 
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previously that [11C]PBR28 binding is influenced by the TSPO genotype and up to a 50 fold 
difference in the uptake of [11C]PBR28 has been shown between HAB and LAB genotypes of 
TSPO [307]. The inclusion of HAB patients ensured maximal opportunity to pick up any 
difference in [11C]PBR28 TSPO signal in this pilot experiment and allowed consistency when 
interpreting the data.  
The present study also assessed cognitive function in patients with PC reporting 
cognitive problems since starting ADT with LHRHa, using a detailed battery of paper-based 
and computerised neuropsychological tests. The neuropsychological tasks employed have 
also been used previously to pick early cognitive changes in clinical studies on 
neurodegenerative disorders, cerebrovascular disease and traumatic brain injury [308, 309]. 
Comparisons were made with a control group comprising of patients with PC matched for age, 
treatment and treatment duration. Patients with prior history of neuropsychiatric problems, 
neurodegenerative disorders or cerebrovascular incidents were excluded and so were the 
patients who were deemed to have cognitive issues before receiving ADT as determined by 
clinical history and MMSE. This study design was adopted based on clinical experience as 
well as the mixed findings from the existing literature which seem to suggest that not all 
patients on LHRHa exhibit cognitive side-effects to a similar extent. A meta-analysis 
conducted previously by Nelson et al. suggested that only 47% to 69% of patients on ADT 
develop cognitive decline [203].  
The current work has shown differences between the two groups of patients on 
neuropsychological testing, demonstrating that some patients may possibly have a 
predisposition to early development of the deleterious cognitive effects of sex hormonal 
suppression as a result of LHRHa therapy. The paper-based tests revealed reduced 
performance in the study group (men reporting cognitive deterioration) on all cognitive 
domains assessed including working memory, attention span, verbal fluency, long term verbal 
memory, recognition, associative learning, verbal recall memory, visuospatial ability and 
executive functions (cognitive flexibility, reasoning ability, strategy-making and processing 
speed), as compared to the control group (mean ADT duration of ~7 months). However, the 
155 
 
difference was only statistically significant in mental flexibility and processing speed, 
associative learning and verbal recall fluency (Table 10). Although the design of the present 
study is uniquely different from all relevant studies conducted previously, but findings are 
consistent with published data suggesting reduction in sex hormones caused by ADT with 
LHRHa to be associated with early development of cognitive impairment and in multiple 
domains [203-206].  
Yang et al. in their cross-sectional study on a Chinese population showed significantly 
impaired cognitive performance on tasks of attention span, processing speed and cognitive 
flexibility in patients who had received 6 months ADT with LHRHa for non-metastatic PC as 
compared to non-ADT patients and healthy controls (P < 0.05). In a longitudinal study 
assessing visual memory, verbal memory, executive function and attention, Gonzales et al. 
have also shown patients with PC receiving ADT to develop cognitive dysfunction within 6 
months of the start of therapy as compared to PC patients not receiving ADT and healthy 
controls (P < 0.05) [205]. Previously, Beer et al. showed a significant decline in processing 
speed and long term verbal memory in PC patients on continuous ADT as compared to healthy 
controls (P < 0.01). However, the mean duration of ADT in their study was much longer (~6 
years) than the current study and results were not stratified for the type of ADT which included 
LHRHa or orchidectomy or a combination of either with an anti-androgen.   
The computerised battery of neuropsychometric tests assessing several cognitive 
areas was used for the first time in this population but did not show any difference between 
the two groups (Table 11). Some of the tests were modified digital versions of the paper-based 
questionnaires but did not contain measures of verbal fluency, verbal memory, verbal recall 
and associative learning which were the main cognitive domains shown to be statistically 
different on the paper-based tests. Further, the participants expressed visible difficulty in 
operating the computer and this lack of computer skills may also have contributed to the 
insignificant findings. 
The observed increased neuroinflammation as evidenced by the greater binding of 
[11C]PBR28 in patients reporting cognitive problems as compared to those who did not notice 
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any cognitive change suggests the presence of predisposing factors that may potentially 
contribute to decline in cognitive ability. Moreover, as demonstrated by the neuropsychological 
testing (Table 10), the differential nature of the cognitive deficits caused by the treatment also 
points in the direction of a multi-factorial pathology. In this regard, genetic polymorphisms have 
recently been implicated as contributing influences on the development of cognitive 
behavioural changes in men on ADT [205]. Other factors such as low educational level, 
advanced age at the onset of treatment, concomitant treatments and co-morbid neurological 
conditions may add to cognitive deterioration particularly in susceptible individuals. 
These current findings highlight the need to ascertain factors that may predispose to 
impairments in cognitive functioning, thereby enabling identification of vulnerable individuals 
who may then be offered alternate PC treatment options mitigating the neurotoxic effects of 
diminished sex hormones due to LHRHa ADT. Parenteral oestrogen, a promising ADT 
modality [275, 279], may provide an alternative as oestrogen’s neuroprotective role has been 
revealed in other clinical contexts [38, 40]. Improved cognitive performance following the use 
of transdermal oestradiol as a second-line agent for androgen insensitive PC has also been 
demonstrated in a previous small study [201]. Further research on the cognitive effects of ADT 
is also warranted to help establish changes in clinical practice involving discussion of the 
potential cognitive risks of LHRHa therapy and careful monitoring of cognitive function during 
treatment. Such work may potentially lead to an era of personalised medicine with a huge 
beneficial impact on the overall QoL of PC survivors and others without PC. 
The study has several limitations. As a cross-sectional study, information about the 
cognitive changes over time from baseline is not provided. It lacks control groups of 
demographically matched healthy men as well as patients with PC not receiving ADT, 
inclusion of whom would have enabled effective comparisons. The high costs of the study 
procedures, particularly PET scans, and limited amount of funding available accounted for 
these limitations in study design. The statistical power of the study is also limited by the small 
sample size. However, this is a pilot exploratory study to generate preliminary data for 
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informing the feasibility and design of larger comprehensive future studies and therefore, no 
power calculation was involved for an estimate of sample size.  
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5.2 Bone study 
BMD measurements are the current standard for assessing osteoporosis and the risk 
of associated fragility fractures [346]. Measured using the 2D DEXA technique, BMD only 
provides an areal measure of bone mass which is one of the many factors influencing bone 
strength. It does not take into account the contribution of other elements such as volumetric 
bone mass and micro-architecture to bone strength [296]. 3D high-resolution micro-CT has 
been used to calculate BVF ex vivo but is clinically inapplicable at present due to the risks of 
high radiation exposure [298]. This present study explored the potential of using low-resolution 
clinical-CT for estimating bone strength as most oncological patients receive CT scans 
clinically for staging tumours and planning interventions.  
The study demonstrated that femoral head trabecular BVF can be calculated (> 90% 
correlation with BVF measured from high-resolution micro-CT images) from CT images 
downgraded in resolution comparable to clinical-CT scans of the pelvic region. BVF metrics 
from these low-resolution scans were also shown to have a 96% correlation with bone strength 
assessed ex vivo. These findings are concordant with results reported by Nazarian et al. who 
studied biopsy specimens of trabecular bone from spine and/or femur of patients with 
metastatic prostate, breast, lung, ovarian, or colon cancer (n=41) and non-cancer cadaveric 
samples (n=96). Specimens were imaged using micro-CT and mechanically tested by uniaxial 
compression. Measured BVF was shown to account for 84% of bone strength variations in all 
trabecular bone specimens irrespective of the skeletal site or pathology [300]. The results of 
the present study show that it is feasible to measure BVF at low voxel size (550um), which is 
the resolution offered by modern clinical CT scanners. The calculated low resolution measures 
of BVF are also highly predictive of bone strength assessed ex vivo (96% correlation) whereas 
BMD has previously been shown to have only a 50% correlation to bone strength [347].  
A limitation of the study is the use of low resolution data downgraded from high-
resolution micro-CT data as a simulation of low resolution clinical-CT data. The micro-CT data 
do not contain the same noise and artefacts that are present in clinical-CT data. Further work 
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using actual clinical CT data for determining BVF and its comparisons with BMD values from 
DEXA and measures calculated from finite element analysis (a method using computer 
modelling to predict effect of loading on mechanical behaviour of bone) is required to provide 
more conclusive results [348]. Future investigations showing that such clinical CT-based 
measurements predict fractures better than the current methods may help establish the 
potential future use of BVF as an easy access, non-invasive and cost-effective method for 
clinical bone health assessment. 
BVF may readily serve as an effective metric for predicting bone strength in cancer 
patients who routinely undergo CT scans of the pelvis as part of their cancer management 
regime and changes in bone strength over time can be tracked using BVF measures derived 
from those CT scans. Timely and accurate identification of high risk patients such as those 
with diminishing BVF can allow clinicians to modify treatment and/or prescribe bone sparing 
agents [349]. Clinical trials of diet and/or exercise intervention for improving bone health can 
potentially utilise BVF instead of BMD [350, 351]. With advancements in CT technology 
leading to reduction in radiation dosage, this novel metric of bone strength could find 
widespread clinical use in the future for diagnosing osteoporosis in the general population, 
predicting fracture risk and monitoring treatment outcomes. BVF can be readily employed as 
a novel metric for predicting bone strength in PC patients receiving ADT with LHRHa. 
As both osteoblastic and osteolytic processes are involved in bone remodelling and 
turnover, metabolites of bone formation and resorption have been used to assess changes in 
skeletal homeostasis following anti-resorptive therapy or treatment with bone forming agents. 
The data on changes in such biochemical parameters of bone metabolism following ADT with 
LHRHa in PC are limited. The present experiment looked at early changes in serum BALP 
levels of patients undergoing ADT for PC. No change was observed in serum BALP levels 
after 3 months of commencement of ADT (Table 13) although serum testosterone and 
oestradiol levels were significantly reduced as compared to baseline concentration and control 
group (p<0.001) Table 14,15). No correlation was found between serum sex hormone and 
BALP levels (Figures 50,51). Unlike these findings, a previous study by Greenspan et al. 
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showed a rise in bone turnover markers in men on ADT for PC. Serum BALP, osteocalcin, 
procollagen type 1 amino-terminal propeptide (P1NP) and urinary NTX were elevated in men 
receiving ADT (n=30) compared with non-ADT users (n=72) and healthy controls (n=43) after 
12 months (p<0.05). Urinary NTX was also elevated after 6 months in men on ADT compared 
with men not on ADT (p<0.05) [352]. Greenspan et al. measured bone markers at 6 and 12 
months from baseline whereas in the present study, BALP was measured at 3 months from 
baseline. Further, the patients in the current study were ADT-naïve at baseline while patients 
included in the study by Greenspan et al. were already on ADT (mean duration of ADT at 
baseline was 2.9 + 1.5 months).  
In another study, Morote et al. showed increased serum BALP levels in patients with 
non-metastatic PC receiving CAB (n=35) over a 5 year follow-up period. After 5 years, there 
was a 65% increase in mean serum BALP concentration from the baseline pre-treatment 
values. The increase was highest (32% from baseline) after the first year of commencement 
of CAB [235].  Morote et al. measured BALP levels annually for five years but changes in 
BALP levels immediately after castration were not determined. 
The present results suggest that biochemical changes in skeletal metabolism as 
reflected by serum BALP levels may not be evident as early as 3 months following ADT with 
LHRHa. However, this study is limited by the small sample size and comparison involving 
baseline and 3 month assessments. Another important limitation is the use of serum BALP 
measurements only which is one of the many markers of bone turnover. A larger prospective 
future study using serial assessments of multiple markers will help in determining the effects 
of acute reduction in sex hormones as a result of ADT on bone metabolism. 
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5.3 Odour study 
The present pilot study investigated changes in odour of patients with PC following 
ADT with LHRHa considering the acute suppression of sex hormones seen with this treatment 
and the possible links between odour and sex steroid metabolism. The study was based on 
earlier work suggesting that body odour is mediated predominantly by axillary secretions and 
that metabolites of sex steroid biosynthetic pathway are important constituents of axillary 
secretions [74]. The results from this experiment did not show any perceived difference in 
odour after 3 months of LHRHa therapy suggesting odour signalling is not affected following 
LHRHa therapy (Tables 16-18). Serum testosterone and oestradiol levels were significantly 
reduced following treatment (p=0.000) (Table 19-21) (Figure 53). 
An important consideration while interpreting these results is that in addition to the 
androstene steroids derived from metabolic pathways involving sex hormones, axillary 
secretions contain a wide array of odorant molecules including cholesterol, cholesteryl esters, 
unsaturated / hydroxylated branched fatty acids and sulfanylalkanols [73]. Thus, the 
suppression of sex hormone production as seen with ADT may not be a major factor 
influencing odour generation. Moreover, serum levels of sex hormones studied are in the 
nano- and pico-molar ranges (Table 20) and potential associated changes in secretory profile 
of axillary glands due to inhibition of sex steroid biosynthesis may not be sufficient to induce 
perceivable alterations in odour. A previous study by Gildersleeve et al. suggested that 
hormonal changes occurring during the menstrual cycle result in perceived differences in 
female odour. Their study showed men to discriminate scents of women in the high-fertility 
phase of menstrual cycle from the low-fertility phase (p<0.001). Men also rated high-fertility 
scents as more attractive than low-fertility scents (p<0.001) [66]. Unlike the present study, 
their study employed cotton gauze pads worn by women in both underarms for a period of 24 
hours to collect odour samples. Differences in sampling method and length have been shown 
to influence perceived body odour quality [342]. 
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Mitro et al. previously highlighted human ability to discriminate age based on emitted 
body odour and that effect was shown to be mediated mainly by odours of old age individuals 
[72]. An earlier study of body odour composition using gas-chromatography mass 
spectrometry (GCMS) detected the presence of 2-Nonenal, a strongly odoriferous aldehyde 
derived from oxidative degradation of fatty acids, only in older individuals (40 years or older) 
and its levels were shown to increase with advancing age [353]. In this current study, odour 
samples were provided by elderly men with PC (average age 69.6 years) and any potential 
changes in odour perception as a result of castration may have been masked by odour 
constituents such as 2-Nonenal which are known to be elevated in the older age group. 
There are several limitations of this study. The sampling technique employed involved 
participant’s wearing T-shirts in bed for two consecutive nights and following the instructions 
provided about dietary restrictions and hygiene. Many studies on odour signalling conducted 
previously employed this sampling method [71, 342, 343]. Although clear directions were given 
and patients were asked about any reservation or problem regarding compliance to those 
instructions, there were no objective means to determine non-adherence to instructions which 
could mask or contaminate the natural odour. Thus, any such deviation from given instructions 
is likely to have affected the outcome. Recruitment and subsequent odour sampling were done 
across all seasons which is another limitation of the study as anecdotal observations suggest 
seasonal variations in axillary sweat production. Personal grooming habits such as shaving of 
axillary hair has also been shown to have an effect on axillary odour [352]. The action of local 
cutaneous microflora on constituents of axillary sweat from apocrine, eccrine and sebaceous 
glands is known to alter odour characteristics [351]. The sampling method used did not control 
for these factors. 
The donor odour samples were rated by young adult male and female volunteers for 
their attractiveness, masculinity and intensity. There is great diversity in human olfaction which 
is known to be mediated mainly by genotypic variations [354]. The reliability of ratings may 
have been compromised due to such variability in rater’s individual olfactory ability although 
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relatively large number of raters were employed to minimise this effect. These inadequacies 
of the sampling methods and subjective assessments need to be revisited in future studies.  
Future work to determine changes in odour profile in the clinical setting of ADT for PC 
should be done using analytical sampling procedures and instrumental techniques like GCMS 
[355-357] which can help identify and quantify any odoriferous component affected by the 
treatment. 
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6. Translational potential and future research 
The cognitive data obtained from this pilot project will help design future research 
studies aimed at developing imaging biomarkers for earlier detection of ADT related cognitive 
decline and to improve understanding of the mechanisms of such worsening in cognitive 
function. Such work can potentially lead to the development of a commercial imaging agent 
for use in the early diagnosis of cognitive deterioration and enable identification of potential 
interventions for slowing / preventing this unwanted and serious treatment complication, 
thereby improving the QoL of not only PC survivors but their families as well. Mechanistic 
information on the development of cognitive dysfunction may provide important information to 
clinicians in assisting patients with PC to choose alternate treatments with potentially reduced 
toxicity (e.g. parenteral oestrogen). The standardised neuropsychometric testing employed in 
this study can also find routine use in the diagnostic and follow-up clinics, to gauge the 
cognitive health of patients under treatment for PC. Highlighting the pathological events in 
cognitive decline associated with contemporary ADT with LHRHa will have significant impact 
on future studies on dementia, far wider than ADT alone. 
The CT-based methodology employed in this project for calculating BVF may possibly 
lead to improved clinical determination of the skeletal status of patients. Further work in-vivo 
on this non-invasive clinically accessible technique for assessment of bone quality may yield 
an efficient diagnostic and treatment modality which can be employed in a range of conditions 
affecting bone health such as ADT for PC. More widely, the BVF measurement technique 
could be useful for identifying early osteoarthritis and osteoporosis that are characterised by 
increasing and decreasing bone mass respectively. Measurement of bone turnover markers 
such as BALP is another approach for evaluating skeletal health which is commonly used in 
the management of postmenopausal women. The present work suggests a limitation of this 
approach as the sole method of monitoring early bone changes in men receiving ADT with 
LHRHa. This may be evaluated further in a larger study and also with alternative treatment 
options (parenteral oestrogen). Combination of skeletal imaging and bone markers can also 
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be investigated in future studies to ascertain their potential for clinical use in monitoring the 
rapid effects of androgen suppression on bone health. 
The odour experiment did not show a change in perceived character of odour following 
LHRHa treatment. However, the study had some limitations which may be overcome in future 
work using objective analytical techniques like GCMS. Documenting changes in body odour 
of men receiving ADT for PC may pave way for investigating the psycho-socio-sexual impact 
of variations in smell signalling on dyadic relationships. Future metabolomic analysis of odour 
profile may help identify and characterise the chemo-signals involved in odour signalling. Such 
work may lead to development of pheromone-like odorants for patients’ use to overcome any 
potential negative impact of ADT on patient-partner relationships. 
The pilot results obtained and the observations noted from the current project will help 
in the development and execution of future comprehensive research studies whose findings 
are likely to benefit a large population of men with PC having iatrogenic sex hormone change 
as a result of ADT. On similar lines, further work can be designed to include other less well- 
studied but serious toxicities of LHRHa treatment like metabolic syndrome, renal and 
haematological problems. Moreover, the scope of this project can be extended to other clinical 
matters which involve physiological, pathological or therapeutic changes in sex hormones 
including menopausal syndrome, hormonal contraception, PCOS and breast cancer in 
females, late-onset hypogonadism and testosterone supplementation in males and gender 
dysphoria in both sexes.  
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Appendix IV – Study Data 
 
Bone Study 
Bone Volume Fraction Experiment 
No. 
  
Femoral Head Bone Volume Fraction measured at different resolutions 
30 µ 50 µ 100 µ 200 400 µ 550 µ 
1 0.17 0.17 0.15 0.17 0.15 0.16 
2 0.26 0.26 0.27 0.26 0.25 0.24 
3 0.22 0.23 0.22 0.22 0.22 0.21 
4 0.21 0.20 0.21 0.20 0.20 0.20 
5 0.25 0.24 0.24 0.24 0.25 0.24 
6 0.21 0.22 0.22 0.22 0.20 0.22 
7 0.26 0.25 0.25 0.25 0.25 0.26 
8 0.19 0.19 0.20 0.19 0.19 0.18 
9 0.21 0.21 0.21 0.21 0.21 0.21 
10 0.21 0.19 0.21 0.21 0.21 0.20 
11 0.24 0.26 0.24 0.24 0.24 0.24 
12 0.27 0.27 0.27 0.27 0.28 0.27 
13 0.20 0.19 0.20 0.20 0.19 0.19 
14 0.28 0.25 0.27 0.27 0.28 0.28 
15 0.25 0.25 0.25 0.25 0.24 0.23 
16 0.27 0.25 0.23 0.27 0.26 0.26 
17 0.17 0.15 0.15 0.15 0.11 0.13 
18 0.18 0.17 0.15 0.12 0.12 0.13 
19 0.22 0.21 0.22 0.22 0.22 0.21 
20 0.25 0.25 0.24 0.24 0.24 0.23 
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Bone alkaline phosphatase experiment 
Sr. No. Group Testosterone 
nmol/L 
Oestradiol 
pmol/L 
BALP 
U/L 
Age 
Years 
1 Control Baseline 20.07 80 24.9 58 
2 Control Baseline 9.19 46 34.2 60 
3 Control Baseline 16.41 126 28.9 72 
4 Control Baseline 14.59 132 27.1 73 
5 Control Baseline 13.61 105 23.1 65 
6 Control Baseline 17.71 73 65 50 
7 Control Baseline 27.7 66 22.4 64 
8 Control Baseline 11.98 175 20.4 53 
9 Control Baseline 10.24 122 42.1 64 
10 Study Baseline 20.3 121 21.3 73 
11 Study Baseline 21.4 79 28.9 67 
12 Study Baseline 9.31 78 16.7 74 
13 Study Baseline 20.44 80 29 69 
14 Study Baseline 10.4 77 17.4 75 
15 Study Baseline 16.08 147 34.4 72 
16 Study Baseline 17.3 87 30.9 75 
17 Study Baseline 17.98 51 33.5 59 
18 Study Baseline 20.23 95 23.3 68 
19 Control 3month 22.55 111 24 58 
20 Control 3month 15.72 111 32 60 
21 Control 3month 9.41 77 35.9 72 
22 Control 3month 12.7 87 28.6 73 
23 Control 3month 12.36 96 24.4 65 
24 Control 3month 18.93 78 56.6 50 
25 Control 3month 18.82 56 24.5 64 
26 Control 3month 20.28 97 65.2 53 
27 Control 3month 2.91 131 34.1 64 
28 Study 3month 0.45 37 45.6 73 
29 Study 3month 0.45 37 21 67 
30 Study 3month 0.45 37 15.7 74 
31 Study 3month 0.45 37 20.3 69 
32 Study 3month 0.45 37 16.2 75 
33 Study 3month 0.45 37 38.6 72 
34 Study 3month 0.45 37 27 75 
35 Study 3month 1.39 37 17.2 59 
36 Study 3month 1.42 37 34 68 
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Cognitive Study 
Paper-based Neuropsychology testing 
No. Age Group MMSE WTAR SM MR DS Pl PD LMI LMD LMR TMA TMB CWCN CWWR CWI CWIS VF 
1 77 CI 28 114 36 19 12 13 1 36 18 25 73 136 49 26 110 114 41 
2 77 CI 24 90 16 8 9 11 0 22 7 17 49 146 67 31 180 180 28 
3 59 CI 29 104 26 7 16 14 3 37 14 22 26 85 38 26 60 56 28 
4 74 CI 24 112 30 18 14 14 2 31 13 25 37 120 37 24 106 90 27 
5 60 Control 27 111 35 21 13 26 8 36 21 25 48 130 44 25 70 80 51 
6 70 Control 24 97 36 18 14 23 7 36 16 21 34 113 41 23 57 65 44 
7 57 Control 29 115 38 25 13 21 8 38 17 24 33 95 30 23 66 78 58 
8 71 Control 28 122 44 23 18 17 5 23 12 23 51 118 33 22 76 88 50 
9 66 Control 29 116 27 9 17 24 6 31 18 23 35 90 35 24 70 76 41 
10 65 Control 30 123 34 20 19 17 7 40 21 25 34 94 29 20 68 65 49 
Key:  
MMSE; Mini-Mental State Examination  WTAR; Wechsler’s Test of Adult Reading SM; Similarities   MR; Matrix Reasoning 
DS; Digit Span     PI; People Test Immediate Recall  PD; People Test Delayed Recall 
LMI; Logical Memory Immediate Recall  LMD; Logical Memory Delayed Recall  LMR; Logical Memory Recognition 
TMA; Trail-making A    TMB; Trail-making B    CWCN; Colour Word Interference Test Colour Naming 
CWWR; Colour Word Interference Test Word Reading      CWI; Colour Word Interference Test inhibition 
CWIS; Colour Word Interference Test Inhibition Switching     VF; Verbal Fluency  
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Computerised Cognitive testing 
No. Age Group Digit 
Span  
Spatial 
Span 
Paired 
Associates 
Self 
Ordered 
Search 
Rotations Feature 
match 
Polygon Monkey 
ladder 
Double 
Trouble 
Verbal 
reasoning 
Odd 
one 
out 
Tree 
Task 
1 77 CI 5 2 2 5 53 56 24 5 9 3 12 6 
2 77 CI 5 3 3 4 33 43 0 4 6 7 11 3 
3 59 CI 6 5 4 8 69 72 34 7 13 14 12 6 
4 74 CI 6 5 3 7 44 72 20 6 3 10 14 6 
5 60 Control 6 5 4 6 18 36 4 7 16 8 8 3 
6 70 Control 5 4 3 6 15 61 13 6 6 3 13 10 
7 57 Control 5 2 3 5 44 56 13 8 8 9 13 3 
8 71 Control 6 3 3 7 46 70 43 6 16 14 13 6 
9 66 Control 4 4 2 6 49 60 22 5 3 3 12 14 
10 65 Control 7 5 4 6 56 132 16 6 5 6 13 10 
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Odour Study 
 
No. Group Age 
Years 
Ethnicity Testosterone 
Baseline 
Testosterone 
3 months 
Oestradiol 
Baseline 
Oestradiol 
3 months 
1 Control 58 S American 20.07 22.55 80 111 
2 Control 60 White 9.19 9.41 46 77 
3 Control 72 Chinese 16.41 15.72 126 111 
4 Control 73 White 14.59 12.7 132 87 
5 Control 65 White 13.61 12.36 105 96 
6 Control 50 Asian 17.71 18.93 73 78 
7 Control 64 White 27.7 18.82 66 56 
8 Control 53 White 11.98 20.28 175 97 
9 Control 74 White 24 22.2 102 107 
10 Control 64 White 10.24 12.91 122 131 
11 Study 73 White 20.3 0.45 121 37 
12 Study 67 White 21.4 0.45 79 37 
13 Study 74 Black 9.31 0.45 78 37 
14 Study 69 Asian 20.44 0.45 80 37 
15 Study 75 Chinese 10.4 0.45 77 37 
16 Study 72 Black 16.08 0.45 147 37 
17 Study 75 White 17.3 0.45 87 37 
18 Study 59 Asian 17.98 1.39 51 37 
19 Study 68 Asian 20.23 1.42 95 37 
20 Study 64 Black 12.24 0.49 79 37 
Units: Testosterone nmol/L, Oestradiol pmol/L 
